Study,Year,Data source,ID: CRS,ID: CTG,Char: Methods,Char: Participants,Char: Interventions,Char: Outcomes,Char: Study registration,Char: Publication details,Char: Stated aim for study,Char: Notes
Aliaev 2010,2010,PUB,22923463,,"<p><b>Study design: </b>prospective, open-label study</p><p><b>Setting/country: </b>single center/Russia</p><p><b>Dates when study was conducted:</b> NA</p>",<p><b>Inclusion criteria:</b></p><ul><li>IIEF-5: 8 to 21 points</li><li>AMS questionnaire: more than 26 points</li><li>IPSS index: lower than 18 points</li><li>Plasma content of TT: less than 12 nmol/L</li><li>PSA: less than 4 ng/mL</li></ul><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>96</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 30</li><li>Age (mean ± SD): 46.67 ± 9.09 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 7.37 ± 2.38 nmol/L</li><li>IIEF-5 (mean ± SD): 14.50 ± 3.87</li><li>PSA (mean ± SD): 0.94 ± 0.34 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 34</li><li>Age (mean ± SD): 48.85 ± 9.48 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA nmol/L</li><li>IIEF-5 (mean ± SD): 15.24 ± 4.1</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group C</b></p><ul><li>Number of all participants randomly assigned: 32</li><li>Age (mean ± SD): 48.94 ± 9.26 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 6.91 ± 2.40 nmol/L</li><li>IIEF-5 (mean ± SD): 14.39 ± 4.2</li><li>PSA (mean ± SD): 1.156 ± 0.3 ng/mL</li></ul>,<p><b>Group A: </b>TU (Nebido®) in the form of 1 injection of 4 mL of a 25% solution IM</p><p><b>Group B:</b> PDE-5 inhibitor (vardenafil 10&nbsp;mg) on demand</p><p><b>Group C:</b> Group A + Group B</p><p><b>Follow-up:</b> 6 weeks</p>,"<p><b>Primary outcomes</b></p><ul><li>Erectile function</li><li>Sexual quality of life</li></ul><p>How measured: IIEF-5, AMS, SEP</p><p>Time points measured: baseline, 6 weeks</p><p>Time points reported: baseline, 6 weeks</p><p><b>Secondary outcomes</b></p><ul><li>Overall satisfaction</li></ul><p>How measured: GAQ</p><p>Time points measured: 6 weeks</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: PSA</p><p>Time points measured: baseline, 6 weeks</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,"<p>To comparatively analyze the effectiveness of monotherapy with PDE-5 inhibitors, testosterone preparations and the combined treatment of erectile dysfunctions associated with androgen deficiency</p>",<p><b>Language of publication: </b>Russian</p>
Allan 2008,2008,PUB,22923465,,<p><b>Study design: </b>double-blind randomized trial</p><p><b>Setting/country:</b> single center/Australia</p><p><b>Dates when study was conducted:</b> May 2001 to April 2004</p>,"<p><b>Inclusion criteria:</b></p><ul><li>Age: 55 years and over</li><li>Serum testosterone level: less than 15 nmol/L</li><li>Non-obese (BMI &lt; 30 kg/m² and waist circumference &lt; 102 cm)</li><li>Non-smokers in good general health</li><li>Symptoms consistent with testosterone deficiency</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Excessive alcohol intake</li><li>History of malignancy (excluding non-melanoma skin cancer)</li><li>Serious chronic medical illness including diabetes mellitus, sleep apnea, prostate cancer, or clinically significant benign prostate disease</li><li>Testosterone therapy in the previous 12 months or testosterone implant</li><li>Symptoms of depression or on antidepressant medication</li></ul><p><b>Total number of participants randomly assigned:</b> 62</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 31</li><li>Age (mean ± SD): 62.1 ± 5.5 years</li><li>BMI (mean ± SD): 26.1 ± 2.3 kg/m²</li><li>Testosterone (mean ± SD): 13.6 ± 2.9 nmol/L</li><li>IIEF-EF (mean ± SD): 13.9 ± 10.2</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 31</li><li>Age (mean ± SD): 64.5 ± 7.5 years</li><li>BMI (mean ± SD): 25.4 ± 2.2 kg/m²</li><li>Testosterone (mean ± SD): 14.5 ± 3.5 nmol/L</li><li>IIEF-EF (mean ± SD): 10.3 ± 8.5</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>androderm patch (5 mg testosterone) + triamcinolone acetonide cream 0.02% (Sigma Pharmaceuticals, Australia)</p><p><b>Group B: </b>placebo</p><p><b>Follow-up:</b> 52 weeks</p>","<p><b>Outcomes</b></p><ul><li>Erectile function</li></ul><p>How measured: IIEF</p><p>Time points measured: baseline, 26, 52 weeks</p><p>Time points reported: baseline, 52 weeks</p><p><b>Safety outcomes: </b>NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: Mayne Pharma Australia Pty Ltd.</p><p>Declarations of interest: Watson Laboratories Inc. (Salt Lake City, UT, USA)</p>",<p>To determine the effects of testosterone therapy on self-reported sexual function as measured by a validated questionnaire</p>,<p><b>Language of publication: </b>English</p>
Aversa 2009,2009,PUB,22923467,,"<p><b>Study design: </b>randomized, placebo-controlled, cross-over study</p><p><b>Setting/country: </b>single center/Italy</p><p><b>Dates when study was conducted: </b>NA</p>",<p><b>Inclusion criteria: </b>middle-aged men with LOH and MS</p><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>30</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 10</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>,"<p><b>Group A: </b>TU IM 1000 mg every 12 weeks</p><p><b>Group B: </b>placebo gel 3 g to 6 g/day for 52 weeks. After 52 weeks, TU IM 1000 mg every 12 weeks for 52 weeks</p><p><b>Follow-up: </b>24 months</p>",<p><b>Outcomes</b></p><ol><li>Metabolic effect</li><li>Body composition</li><li>Psychological changes</li><li>Sexual quality of life</li></ol><p>How measured:</p><ol><li>NCEP-ATP III and IDF criteria</li><li>DEXA</li><li>Beck’s Depression scores</li><li>AMS</li></ol><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Safety outcomes: </b>NR</p><p><b>Subgroup:</b> none</p>,<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: none</p>,<p>To evaluate body-composition and psychological effects of IM long-acting TU in middle-aged patients with LOH and MS compared with placebo</p>,<p><b>Language of publication: </b>English</p>
Aversa 2010a,2010,PUB,22923470,,"<p><b>Study design: </b>randomized, double-blind, double-dummy study</p><p><b>Setting/country: </b>single center/Italy</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Age: between 50 and 65 years</li><li>History: MS and/or T2DM</li><li>Serum TT level: &lt; 3.20 ng/mL (11 nmol/L) or calculated FT levels: &lt; 250 pmol/L (10 pg/mL)</li><li>Two symptoms of hypogonadism</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Androgen therapy or anabolic steroids within 12 months of entry into the study</li><li>5-α-reductase inhibitors</li><li>History: cancer, drug or alcohol abuse, symptomatic OSAS, blood coagulation irregularities, uncontrolled thyroid disorders, uncontrolled diabetes(HbA1c ≥ 11)</li><li>Polycythemia (hematocrit level ≥ 52%)</li><li>Elevated PSA level</li><li>Abnormal DRE</li><li>Hyperprolactinemia or organic hypothalamic-pituitary pathology</li><li>Severe cardiac disease (NYHA class III or above)</li><li>Severe hepatic disease(ALT/AST ≥ 3 times above the upper limit of normal range)</li><li>Renal insufficiency (serum creatinine ≥ 1.5)</li><li>Severe neurological and psychiatric disease</li><li>Requiring or undergoing fertility treatment</li></ul><p><b>Total number of participants randomly assigned:</b> 52</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 32</li><li>Age (mean ± SD): 58 ± 10 years</li><li>BMI (mean ± SD): 30 ± 4.5 kg/m²</li><li>Testosterone (mean ± SD): 8.25 ± 2.1 nmol/L</li><li>IIEF-5 (mean ± SD): 17 ± 2</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 10</li><li>Age (mean ± SD): 57 ± 8 years</li><li>BMI (mean ± SD): 32.5 ± 5.5 kg/m²</li><li>Testosterone (mean ± SD): 8.91 ± 2.1 nmol/L</li><li>IIEF-5 (mean ± SD): 17 ± 3</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group C</b></p><ul><li>Number of all participants randomly assigned: 10</li><li>Age (mean ± SD): 55 ± 5 years</li><li>BMI (mean ± SD): 31 ± 6.2 kg/m²</li><li>Testosterone (mean ± SD): 8.91 ± 2.1 nmol/L</li><li>IIEF-5 (mean ± SD): 16 ± 2</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A:</b> TU IM 1000 mg/4 mL 12 weeks from week 6 for 12 months</p><p><b>Group B: </b>oral TU 40 mg/twice for 6 months + intramuscular TU 1000 mg/4 mL for 6 additional months</p><p><b>Group C: </b>placebo gel 3 g to 4g/day for 12 months</p><p><b>Follow-up: </b>12 months</p>,"<p><b>Primary outcomes</b></p><ol><li>Erectile function</li><li>Sexual quality of life</li><li>Body composition</li><li>Laboratory outcomes</li></ol><p>How measured:&nbsp;</p><ol><li>IIEF-5 and sexual domain of AMS</li><li>Total AMS score</li><li>Waist circumference, BMI, DEXA</li><li>TT and FT, SHBG, estradiol, HOMA-IR</li></ol><p>Time points measured: baseline, 6, 12 months</p><p>Time points reported: baseline, 6, 12 months</p><p><b>Secondary outcomes</b></p><ol><li>Lower urinary tract symptoms</li><li>Prostate-related events</li></ol><p>How measured:&nbsp;</p><ol><li>IPSS</li><li>Serum PSA level</li></ol><p>Time points measured:&nbsp;</p><ol><li>Baseline, 6, 12 months</li><li>Baseline, 3, 6, 9, 12 months</li></ol><p>Time points reported:&nbsp;</p><ol><li>Baseline, 6, 12 months</li><li>Baseline, 3, 6, 9, 12 months</li></ol><p><b>Safety outcomes</b></p><p>How measured: hematocrit level</p><p>Time points measured: during the course of study</p><p>Time points reported: during the course of study</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To investigate the efficacy and safety of two different preparations of TU in 52 hypogonadal men with MS</p>,<p><b>Language of publication: </b>English</p>
Aversa 2010b,2010,PUB,22923473,,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled study</p><p><b>Setting/country: </b>single center/Italy</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Age: between 45 and 65 years</li><li>History: MS and/or T2DM</li><li>TT serum level below 3.0 ng/mL (11 nmol/L) or calculated free FT levels &lt; 250 pmol/L (10 pg/mL)</li><li>At least two symptoms of hypogonadism</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Androgen therapy or anabolic steroids in the previous 12 months</li><li>History: tumors, blood coagulation irregularities, symptomatic OSAS, polycythemia (hematocrit level ≥ 52%), drug or alcohol abuse</li><li>Elevated PSA level or abnormal DRE</li><li>Using 5-a-reductase inhibitors</li><li>Presence of any uncontrolled endocrine disorder including diabetes (HbA1c ≥ 9)</li><li>Heart failure (NYHA III or IV)</li><li>Hepatic or renal insufficiency</li><li>Severe neurological and psychiatric disease</li><li>Requiring or undergoing fertility treatment</li></ul><p><b>Total number of participants randomly assigned:</b> 50</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 40</li><li>Age (mean ± SD): 58 ± 10 years</li><li>BMI (mean ± SD): 30.2 ± 4.5 kg/m²</li><li>Testosterone (mean ± SD): 8.33 ± 2.4 nmol/L</li><li>IIEF (mean ± SD): NA</li><li>PSA (mean ± SD): 1.07 ± 0.4 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 10</li><li>Age (mean ± SD): 57 ± 8 years</li><li>BMI (mean ± SD): 31 ± 6.2 kg/m²</li><li>Testosterone (mean ± SD): 9 ± 1.7 nmol/L</li><li>IIEF (mean ± SD): NA</li><li>PSA (mean ± SD): 1.1 ± 0.5 ng/mL</li></ul>",<p><b>Group A: </b>TU (Nebid) 1000 mg/ 12 weeks from week 6 for 24 months</p><p><b>Group B: </b>placebo gel 3 g to 4g/daily for 24 months</p><p><b>Follow-up: </b>24 months</p>,"<p><b>Primary outcomes</b></p><ul><li>Variation from baseline in the HOMA-IR, CIMT, and hsCRP</li></ul><p>How measured: CIMT: ultrasound equipped with a 7.5 MHz to 13 MHz broadband linear array transducer with standard software (Sonocalc IMT). HOMA-IR and hs-CRP: blood test</p><p>Time points measured: baseline and every 3months</p><p>Time points reported: baseline and every 3months</p><p><b>Secondary outcomes</b></p><ul><li>Variation from baseline in hormonal, biochemical, and anthropometric measurements by DXA</li></ul><p>How measured: blood test, DXA</p><p>Time points measured: baseline and every 3 months</p><p>Time points reported: baseline and every 3 months</p><p><b>Safety outcomes</b></p><p>How measured: hematocrit level 52%; PSA level increased &gt; 1.0 ng/mL above the baseline PSA if baseline PSA was &lt; 2.0 ng/mL; PSA level increase &gt; 50% of the baseline PSA if baseline PSA was &gt; 2.0 ng/mL</p><p>Time points measured: during the course of study</p><p>Time points reported: during the course of study</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: none</p>,<p>To evaluate the effects of parenteral TU in outpatient clinic patients with MS and late-onset hypogonadism</p>,<p><b>Language of publication: </b>English</p>
Aydin 1996,1996,PUB,22923475,,<p><b>Study design: </b>randomized trial</p><p><b>Setting/country: </b>single center/Turkey</p><p><b>Dates when study was conducted: </b>NA</p>,<p><b>Inclusion criteria: </b>men of various ages complaining of an inability to create or maintain an erection sufficient for intercourse</p><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>79</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 21</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group C</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group D</b></p><ul><li>Number of all participants randomly assigned: 18</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>,<p><b>Group A:</b> TU 120 mg/day IM</p><p><b>Group B:</b> trazodone 150 mg/day</p><p><b>Group C:</b> hypnotic suggestion</p><p><b>Group D:</b> placebo</p><p><b>Follow-up:</b> 16 weeks</p>,<p><b>Outcomes</b></p><ul><li>Sexual function</li></ul><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Safety outcomes</b>: NA</p><p><b>Subgroup:</b> none</p>,<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: none</p>,<p>To examine the effects of hypnotic suggestions or the administration of testosterone or trazodone to impotent men with no detectable organic cause for the impotence.</p>,<p><b>Language of publication: </b>English</p>
Behre 2012,2012,PUB,22923477,,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled trial</p><p><b>Setting/country: </b>multicenter/Europe</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Age: 50 to 80 years</li><li>Symptoms of testosterone deficiency</li></ul><p>Diagnosis of symptomatic testosterone deficiency required all of the following:</p><ul><li>Serum TT &lt; 15 nmol/L (&lt; 4.3 ng/mL)</li><li>Bioavailable testosterone &lt; 6.68 nmol/L (&lt; 1.93 ng/mL)</li><li>AMS rating scale total score &gt; 36</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Contraindication or hypersensitivity to 1% testosterone gel</li><li>BMI &gt; 35 kg/m²</li><li>PSA level ≥ 4 ng/mL</li><li>Severe symptomatic benign prostatic hyperplasia (IPSS ≥ 20)</li><li>Hematocrit &gt; 50%</li><li>Prolactin &gt; 25 ng/mL</li><li>Metallic implants</li><li>Concurrent use of cytochrome P450-inducing medications, corticotrophins, or oxyphenbutazone</li><li>History: prostate or breast cancer, sleep apnea, polycythemia, hypothalamic pituitary disorders, psychiatric disorders, uncontrolled diabetes mellitus or diabetes mellitus with vascular changes, uncontrolled thyroid disorders, hypertension or epilepsy; and severe cardiac, and hepatic or renal insufficiency</li></ul><p><b>Total number of participants randomly assigned:</b> 362</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 183</li><li>Age (mean ± SD): 61.9 ± 6.6 years</li><li>BMI (mean ± SD): 28.5 ± 3.3 kg/m²</li><li>Testosterone (mean ± SD): 10.4 ± 2.6 nmol/L</li><li>Sexual domain of AMS (mean ± SD): 16.0 ± 3.1</li><li>PSA (median, range): 1.25 (0.1-3.7) ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 179</li><li>Age (mean ± SD): 62.1 ± 6.3 years</li><li>BMI (mean ± SD): 28.7 ± 3.0 kg/m²</li><li>Testosterone (mean ± SD): 10.6 ± 2.6 nmol/L</li><li>Sexual domain of AMS (mean ± SD): 15.7 ± 3.0</li><li>PSA (median, range): 1.31 (0.2 to 3.7) ng/mL</li></ul>",<p><b>Group A: </b>testosterone gel 5 g/day</p><p><b>Group B: </b>placebo</p><p><b>Follow-up:</b> 6 months</p>,"<p><b>Primary outcomes</b></p><ol><li>Lean body mass</li><li>Erectile function</li><li>Sexual quality of life</li></ol><p>How measured:&nbsp;</p><ol><li>DEXA</li><li>Sexual domain of AMS</li><li>AMS total score</li></ol><p>Time points measured: baseline, 6 months</p><p>Time points reported: baseline, 6 months</p><p><b>Secondary outcomes</b></p><ol><li>Prostate-related events</li><li>Lower urinary tract symptoms</li><li>Laboratory outcomes</li></ol><p>How measured:</p><ol><li>DRE and serum PSA level</li><li>IPSS</li><li>testosterone</li></ol><p>Time points measured: baseline, 6 months</p><p>Time points reported: baseline, 6 months</p><p><b>Subgroup:</b> lean body mass, AMS total score</p><ul><li>Age: &lt; 60, 60 to 80, ≥ 80</li><li>Testosterone: &lt; 10, 10 to 12, ≥ 12</li><li>BMI: &lt; 30, ≥ 30</li></ul>",<p>NA</p>,"<p>Funding sources: Bayer Pharma AG, Berlin, Germany</p><p>Declarations of interest: grant and/or lecture fees from Bayer Pharma, and employment by Bayer Pharma</p>",<p>To investigate the efficacy and safety of treatment with a 1% testosterone gel in men aged 50 to 80 years with hypogonadal to low-normal serum TT (&lt; 15.0 nmol/L) and bioavailable serum testosterone lower than 6.68 nmol/L along with putative symptoms of testosterone deficiency.</p>,<p><b>Language of publication: </b>English</p>
Benkert 1979,1979,PUB,22923479,,<p><b>Study design: </b>double-blind comparison</p><p><b>Setting/country: </b>multicenter/Germany</p><p><b>Dates when study was conducted: </b>NA</p>,"<p><b>Inclusion criteria:</b></p><ul><li>Sexual impotence with reduced or nonexistent ability to have an erection during intercourse persistent for at least 1 year, due to unknown etiology, and a prior history of normal penile erection</li><li>Age: under 60 years old</li><li>Regular female sexual partner, at least 1 attempt at coitus per week</li><li>Normal findings in an andrological examination</li></ul><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>36</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 18</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 20.1 ± 6.4 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 18</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 17.2 ± 7.1 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>TU (oral) 120 mg/day (80 mg at 8 am, 40 mg at 8 pm)</p><p><b>Group B: </b>placebo (2 capsules in the morning, 1 capsule in the evening)</p><p><b>Follow-up: </b>20 weeks</p>","<p><b>Primary outcomes</b></p><ul><li>Androgen treatment influences sexual impotence in males without clinical signs of androgen deficiency</li></ul><p>How measured: Clinical Global Impressions Scale</p><p>Time points measured: every other week</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ol><li>Effects of androgen treatment on the hypothalamic, pituitary-gonadal axis</li><li>Psychological function</li></ol><p>How measured:</p><ol><li>Blood test</li><li>Self-rating scales for depression (Befindlichkeits-Skale) and for somatic disturbances (Beschwerdeliste)</li></ol><p>Time points measured:</p><ol><li>Blood test: first placebo period and after the 10th week of study</li><li>Psychological functions: every other week</li></ol><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: side effects</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,"<p>To determine on a large-scale, blind basis whether androgen treatment influences sexual impotence in males without clinical signs of androgen deficiency.</p>",<p><b>Language of publication: </b>English</p>
Boyanov 2003,2003,PUB,22923481,,"<p><b>Study design: </b>open-label, randomized, no-treatment controlled study</p><p><b>Setting/country: </b>single center/Bulgaria</p><p><b>Dates when study was conducted: </b>NA</p>",<p><b>Inclusion criteria:</b></p><ul><li>Aged between 45 and 65 years</li><li>Be married or living in a stable relationship with a female sexual partner for at least 6 months</li><li>Waist-hip ratio of at least 0.9</li><li>Type 2 diabetes mellitus and symptoms of andropause or erectile dysfunction</li><li>Serum testosterone levels below the normal range for young adults or in the lower third of this range (TT &lt; 15.1 nmol/L)</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Concurrent illnesses other than diabetes or surgical interventions likely to impair sexual function</li><li>Severe diabetic complications such as amputations or chronic renal failure</li><li>Drug use other than antidiabetic medication or antihypertensive</li><li>History of alcoholism or major psychopathology</li><li>Any sign or evidence of prostate enlargement or abnormalities</li></ul><p><b>Total number of participants randomly assigned:</b> 48</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 24</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): 31.08 ± 4.79 kg/m²</li><li>Testosterone (mean ± SD): 9.56 ± 2.33 nmol/L</li><li>Partial Androgen Deficiency of the Aging Male (mean ± SD): 2.25 ± 0.675</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 24</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): 31.01 ± 4.90 kg/m²</li><li>Testosterone (mean ± SD): 10.76 ± 3.0 nmol/L</li><li>Partial Androgen Deficiency of the Aging Male (mean ± SD): 2.50 ± 0.75</li><li>PSA (mean ± SD): NA</li></ul>,<p><b>Group A: </b>TU 120 mg (80 mg at breakfast 40 mg at dinner) oral</p><p><b>Group B: </b>no treatment</p><p><b>Follow-up:</b> 3 months</p>,"<p><b>Primary outcomes</b></p><ol><li>Erectile function</li><li>Sexual quality of life</li><li>Body composition</li><li>Glucose homeostasis</li></ol><p>How measured:</p><ol><li>IIEF-5</li><li>PADAM questionnaire</li><li>Tetrapolar body composition analyzer</li><li>HbA1c determinations and urine analysis</li></ol><p>Time points measured: baseline, 3 months</p><p>Time points reported: baseline, 3 months</p><p><b>Safety outcomes</b></p><p>How measured: adverse events (spontaneous reporting and active questioning)</p><p>Time points measured: 3 months</p><p>Time points reported: 3 months</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,"<p>To assess the effects of oral testosterone supplementation therapy on glucose homeostasis, obesity and sexual function in middle-aged men with type 2 diabetes and mild androgen deficiency</p>",<p><b>Language of publication: </b>English</p>
Brock 2016,2016,PUB,22923483,NCT01816295,"<p><b>Study design: </b>randomized, multicenter, double-blind, placebo-controlled, parallel-group</p><p><b>Setting/country: </b>multicenter//Canada, Europe, South Korea, USA</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria: </b>men 18 years old or older with 2 TT levels less than 300 ng/dL (11 nmol/L) measured 1 week or more apart and at least 1 symptom of testosterone deficiency</p><p><b>Exclusion criteria:</b></p><ul><li>HbA1c greater than 11%</li><li>BMI greater than 37 kg/m<sup>2</sup></li><li>Hematocrit 50% or greater</li><li>History: prostate cancer, breast cancer, other active cancer (except non-melanoma skin cancer)</li><li>Abnormal DRE</li><li>PSA 4 ng/mL or greater at screening</li></ul><p><b>Total number of participants randomly assigned: </b>715</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 358</li><li>Age (mean ± SD): 54.7 ± 10.6 years</li><li>BMI (mean ± SD): 30.3 ± 4.1 kg/m²</li><li>Testosterone (mean ± SD): 7.0 ± 2.3 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 357</li><li>Age (mean ± SD): 55.9 ± 11.4 years</li><li>BMI (mean ± SD): 30.9 ± 4.2 kg/m²</li><li>Testosterone (mean ± SD): 7.0 ± 2.3 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>60 mg topical testosterone solution 2% once daily. If required, the dose was decreased to 30 mg or increased in 30 mg increments up to a maximum of 120 mg daily.</p><p><b>Group B: </b>placebo solution</p><p><b>Follow-up: </b>12 weeks</p>","<p><b>Primary outcomes</b></p><ol><li>Laboratory outcomes</li><li>Erectile function</li><li>Sexual quality of life</li></ol><p>How measured:&nbsp;</p><ol><li>Serum TT</li><li>Erectile function domain of IIEF</li><li>Satisfaction domain of IIEF</li></ol><p>Time points measured:</p><ol><li>Baseline, 2, 6, 12 weeks</li><li>NA</li><li>NA</li></ol><p>Time points reported:</p><ol><li>NA</li><li>12 weeks</li><li>12 weeks</li></ol><p><b>Secondary outcomes</b></p><ol><li>Levels of sexual arousal, interest, and drive</li><li>Levels of energy</li><li>Energy and sexual drive</li></ol><p>How measured:</p><ol><li>Sexual Arousal, Interest and Drive scale</li><li>Hypogonadism Energy Diary</li><li>PGI-I, IIEF, Psychosexual Daily Questionnaire</li></ol><p>Time points measured: NA</p><p>Time points reported:</p><ol><li>Baseline, 4, 12 weeks</li><li>Baseline, 4, 12 weeks</li><li>PGI-I: 12 weeks/ IIEF, Psychosexual Daily Questionnaire: 12 weeks</li></ol><p><b>Safety outcomes</b></p><p>How measured: treatment-emergent adverse events</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NCT01816295</p>,<p>Funding sources: Eli Lilly and Co.</p><p>Declarations of interest: financial interest and/or other relationship with Eli Lilly</p>,"<p>To determine the effect of testosterone solution 2% on TT level and the 2 symptoms of hypogonadism, sex drive, and energy level</p>",<p><b>Language of publication: </b>English</p>
Buvat 2011,2011,PUB,22923490,NCT00244023,"<p><b>Study design: </b>randomized, multicenter, multinational, double-blind, placebo-controlled study</p><p><b>Setting/country: </b>multicenter/Europe</p><p><b>Dates when study was conducted:</b> October 2005 to July 2007</p>","<p><b>Inclusion criteria:</b></p><ul><li>ED complaint ongoing for over 3 months</li><li>Age: between 45 and 80 years old</li><li>Stable heterosexual relationship for more than 3 months and anticipates having the same partner for the whole study</li><li>Not responded adequately to the highest available dosage of tadalafil or other PDE5 inhibitors</li><li>Low or low-to-normal serum testosterone level</li><li>Agrees to make at least 4 attempts at sexual intercourse on 4 separate days during the 4-week run-in period with daily tadalafil 10 mg</li><li>At least 50% of attempts during this period must be unsuccessful</li><li>Agrees not to use any other ED drug or non-drug treatment during the full course of the study</li><li>Providing a signed informed consent</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Impotence caused by other primary sexual disorder</li><li>BMI &gt; 35 kg/m<sup>2</sup></li><li>SBP &gt; 170 or &lt; 90 mmHg or DBP &gt; 110 or &lt; 50 mmHg</li><li>PSA: upper than the normal range</li><li>Extensive skin abnormalities that could affect the absorption of the gel</li><li>Hypersensitivity: Cialis (tadalafil), the active substances or any of the excipients of Androgel®/Testogel®</li><li>Use of androgen therapy or anabolic steroids within 6 months of entry into the study</li><li>Unwilling to cease use of vacuum devices, intracavernosal injection, Viagra, or other therapy for ED</li><li>Seeking conception or treatment for infertility</li><li>Concurrent participation in another clinical trial within 1 month of entry into this study or throughout the duration of the study</li><li>Previous randomization into this study</li><li>Other histories of diseases or drugs like hyperprolactinemia, severe hepatic impairment, cardiac diseases, DHEA and anabolic steroids, and antiandrogens</li><li>Illiteracy, lack of fluency in the language used for the writing of the protocol and questionnaires, unwillingness, medical, psychiatric, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to understand or complete diary or questionnaires or otherwise comply with the trial protocol, or to complete the study</li></ul><p><b>Total number of participants randomly assigned:</b> 173</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 87</li><li>Age (mean ± SD): 58.33 ± 7.56 years</li><li>BMI (mean ± SD): 27.87 ± 4.19 kg/m²</li><li>Testosterone (mean ± SD): 11.7 ± 6 nmol/L</li><li>IIEF-EF (mean ± SD): 15.5 ± 4.2</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 86</li><li>Age (mean ± SD): 59.93 ± 7.38 years</li><li>BMI (mean ± SD): 27.64 ± 3.26 kg/m²</li><li>Testosterone (mean ± SD): 11.7 ± 6 nmol/L</li><li>IIEF-EF (mean ± SD): 15.8 ± 4.1</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>testosterone 50 mg in 5 g of gel + tadalafil 10 mg/day for 12 weeks</p><p><b>Group B: </b>placebo gel (5 g) + tadalafil 10 mg/day for 12 weeks</p><p><b>Follow-up:</b> 16 weeks</p>,"<p><b>Primary outcomes</b></p><ol><li>Erectile function</li><li>Sexual quality of life</li></ol><p>How measured:</p><ol><li>IIEF-EF, GAQ</li><li>AMS</li></ol><p>Time points measured: baseline, 4, 8, 12, 16 weeks</p><p>Time points reported: baseline, 4, 8, 12, 16 weeks</p><p><b>Secondary outcomes</b></p><ol><li>Mean scores on the 4 other domains of the IIEF, and on the whole IIEF</li><li>% of ""Yes"" responses to questions 2, 3, 4, and 5 of the SEP</li><li>Prostate-related events (PSA level, DRE)</li></ol><p>Time points measured:</p><ol><li>Baseline, 4, 8, 12, 16 weeks</li><li>Baseline, 4, 8, 12, 16 weeks</li><li>Baseline, 16 weeks</li></ol><p>Time points reported:</p><ol><li>Baseline, 4, 8, 12, 16 weeks</li><li>Baseline, 4, 8, 12, 16 weeks</li><li>Baseline, 16 weeks</li></ol><p><b>Safety outcomes</b></p><p>How measured: hematocrit</p><p>Time points measured: baseline, 16 weeks</p><p>Time points reported: baseline, 16 weeks</p><p><b>Subgroup:</b> IIEF-EF, SEP-3</p><ul><li>Testosterone: ≤ 4, ≤ 3.46, ≤ 3, ≤ 2.31</li></ul>",<p>NCT00244023</p>,"<p>Funding sources: Bayer-Schering Pharma, Lilly, Besins International</p><p>Declarations of interest: authors served as investigator, speaker, or advisor for Bayer-Schering Pharma, Eli-Lilly, Pfizer, Prostrakan, Auxilium</p>",<p>To confirm the add-on effect of T in men optimally treated with PDE5Is and to specify the baseline T levels at which such an effect becomes significant</p>,<p><b>Language of publication: </b>English</p>
Carroll 1984,1984,PUB,22923496,,"<p><b>Study design: </b>double-blind, cross-over comparison</p><p><b>Setting/country: </b>single center/UK</p><p><b>Dates when study was conducted: </b>From May 1981 to December 1982</p>","<p><b>Inclusion criteria: </b>men aged 19 years old or older presenting complaint of difficulty in achieving or maintaining a full erection during sexual activity, not secondary to loss of sexual interest or obvious physical or mental illness</p><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned:</b> 10</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 5</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 5</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>testosterone IM (testosterone propionate 30 mg, testosterone phenylpropionate 60 mg, testosterone isocaproate 60 mg, testosterone decanoate 100 mg)</p><p><b>Group B: </b>placebo injection</p><p><b>Follow-up: </b>16 weeks</p>","<ul><li>Erectile function</li></ul><p>How measured: daily diaries (waking erection, sexual activity)</p><p>Time points measured: daily</p><p>Time points reported: weekly</p><p><b>Safety outcomes</b>: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>Testosterone treatment would be beneficial for those whose principal complaint was loss of sexual interest but not for those with erectile dysfunction as their principal problem</p>,<p><b>Language of publication: </b>English</p>
Chiang 2007,2007,PUB,22923498,,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled trial</p><p><b>Setting/country: </b>multicenter/Taiwan</p><p><b>Dates when study was conducted: </b>from November 2002 to November 2004</p>","<p><b>Inclusion criteria:</b></p><ul><li>Age: between 20 and 75 years</li><li>Men diagnosed with testosterone deficiency that required testosterone replacement were considered eligible</li><li>Men had never taken androgen replacement therapy or withdrawn from testosterone supplements (including food supplements like DHEA) for 6 weeks before the study began</li><li>Hypogonadal men were eligible if their morning serum testosterone concentrations were &lt; 300 ng/dL. If TT was ≥ 300 ng/dL, FT concentrations were to be &lt; 8.7 pg/mL</li></ul><p><b>Exclusion criteria:&nbsp;</b></p><p>Men with the following.</p><ul><li>Abnormal prostate levels of IPSS &gt; 25</li><li>Prostatic masses or induration on rectal examination or elevated levels of PSA &gt; 4 ng/mL or maximum urine flow rate of &lt; 10 mL/s or hematocrit &gt; 50%</li><li>History or evidence of pulmonary, renal, hepatic, neurological, musculoskeletal, or cardiovascular disease that might affect the outcome of the study or would place him at risk</li><li>Taking drugs that might interfere with the study results (for example, paroxetine, clomipramine, antiandrogen, estrogens, p450 enzyme inducers, barbiturates, oxyphenbutazone, adrenocorticotropic hormone or corticosteroids)</li><li>Major psychiatric illness, sleep apnea, significant systemic illness, active alcoholism, history of drug abuse within the past 5 years</li><li>Body mass index (BMI) &gt; 27.0 or &lt; 18.5</li><li>Generalized skin disease that might affect the absorption of testosterone or prolactin levels &gt; 40 μg/L</li><li>Some men were excluded from this study because of their wives’ disagreements</li></ul><p><b>Total number of participants randomly assigned: </b>40</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): 20 to 75 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 7.4 ± 5.5 nmol/L</li><li>IIEF-5 (mean ± SD): 10.7 ± 4.9</li><li>PSA (mean ± SD): 1.0 ± 0.8 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): 20 to 75 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 9.1 ± 6.9 nmol/L</li><li>IIEF-5 (mean ± SD): 13.9 ± 6.6</li><li>PSA (mean ± SD): 0.7 ± 1.1 ng/mL</li></ul>",<p><b>Group A: </b>50 mg testosterone gel (AndroGel) in 5 g sachets once daily</p><p><b>Group B: </b>placebo gel once daily</p><p><b>Follow-up: </b>3 months</p>,"<p><b>Primary outcomes</b></p><ol><li>Erectile function</li><li>Laboratory outcomes</li></ol><p>How measured:</p><ol><li>IIEF-5/ IIEF-15</li><li>TT, FT, DHT, estradiol, LH, FSH and SHBG</li></ol><p>Time points measured: baseline, 3 months</p><p>Time points reported: baseline, 3 months</p><p><b>Secondary outcomes</b></p><ol><li>Prostate-related events</li><li>Lower urinary tract symptoms</li></ol><p>How measured:&nbsp;</p><ol><li>DRE, serum PSA level</li><li>IPSS</li></ol><p>Time points measured:&nbsp;</p><ol><li>DRE: baseline, 3 months/ PSA: 3 months</li><li>IPSS: baseline, 3 months</li></ol><p>Time points reported: baseline, 3 months</p><p><b>Safety outcomes</b></p><p>How measured: not described</p><p>Time points measured: likely cumulated</p><p>Time points reported: likely cumulated</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: Orient Europharma Co., Ltd.</p><p>Declarations of interest: NR</p>","<p>To evaluate the efficacy and safety of 50 mg/day of TTG, applied on non-scrotal skin, for hypogonadal men in Taiwan</p>",<p><b>Language of publication: </b>English</p>
Gilbert 1992,1992,PUB,22923503,,"<p><b>Study design: </b>randomized, double-blind, cross-over clinical trial</p><p><b>Setting/country: </b>single center/USA</p><p><b>Dates when study was conducted: </b>NA</p>",<p><b>Inclusion criteria: </b>men with low testosterone and impotence</p><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>NA</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned:<b> </b>NA</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD):<b> </b>NA</li><li>Testosterone (mean ± SD):<b> </b>NA</li><li>EF (mean ± SD):<b> </b>NA</li><li>PSA (mean ± SD):<b> </b>NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned:<b> </b>NA</li><li>Age (mean ± SD):<b> </b>NA</li><li>BMI (mean ± SD):<b> </b>NA</li><li>Testosterone (mean ± SD):<b> </b>NA</li><li>EF (mean ± SD):<b> </b>NA</li><li>PSA (mean ± SD):<b> </b>NA</li></ul>,"<p><b>Group A: </b>testosterone enanthate IM, 200 mg every 2 weeks for 3 doses</p><p><b>Group B: </b>normal saline</p><p><b>Follow-up: </b>6 weeks</p>",<ul><li>Sexual function</li></ul><p>How measured: sexual questionnaire and Rigiscan</p><p>Time points measured:<b> </b>NA</p><p>Time points reported:<b> </b>NA</p><p><b>Safety outcomes</b></p><p>How measured:<b> </b>NA</p><p>Time points measured:<b> </b>NA</p><p>Time points reported:<b> </b>NA</p><p><b>Subgroup:</b> none</p>,<p>NA</p>,<p>Funding sources:<b> </b>NR</p><p>Declarations of interest:<b> </b>NR</p>,<p>To evaluate the effect of testosterone enanthate in impotent men with low or low-normal serum testosterone levels</p>,<p><b>Language of publication: </b>English</p>
Giltay 2010,2010,PUB,22923505,NCT00696748,"<p><b>Study design: </b>randomized, placebo-controlled, double-blind, phase III trial</p><p><b>Setting/country: </b>single center/Russia</p><p><b>Dates when study was conducted: </b>October 2005 to October 2008</p>","<p><b>Inclusion criteria: </b>men aged between 35 and 70 years old, with total testosterone levels below 12.0 nmol/L or a calculated free testosterone level below 225 pmol/L, and a diagnosis of MS</p><p><b>Exclusion criteria:</b></p><ul><li>Participation in another clinical study</li><li>Incapable of giving informed consent or incapable of meeting the necessary testing specified in the study protocol</li><li>Having a serious organic or mental disease diagnosed by a psychiatrist (e.g. major depression currently treated with antidepressant medication) suspected on the basis of medical history and/or clinical examination</li><li>Having prostate cancer, breast cancer or suspicion thereof</li><li>Presence or history of hepatic tumors</li><li>Having acute or chronic hepatic disease</li><li>Presence of kidney disease with renal failure</li><li>Having abnormalities in biochemical or hematological laboratory values, whether associated with clinical manifestations of disease or not</li><li>Suspected lack of the participant’s compliance</li><li>Hypersensitivity to the active substance</li></ul><p><b>Total number of participants randomly assigned: </b>184</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 113</li><li>Age (mean ± SD): 51.6 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 7.7 nmol/L</li><li>IIEF-5 (mean ± SD): 13.0</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 71</li><li>Age (mean ± SD): 52.8 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 8.4 nmol/L</li><li>IIEF-5 (mean ± SD): 14.1</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>testosterone undecanoate 1000 mg IM at baseline, and after 6 and 18 weeks</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>30 weeks</p>","<p><b>Primary outcomes</b></p><ol><li>Depressive and aging male symptoms</li><li>Erectile function</li><li>Sexual quality of life</li></ol><p>How measured:</p><ol><li>The Beck Depression Inventory</li><li>IIEF-5</li><li>AMS scale</li></ol><p>Time points measured: baseline, 18 and 30 weeks</p><p>Time points reported: baseline, 18 and 30 weeks</p><p><b>Secondary outcomes</b></p><ul><li>BMI</li><li>LDL and HDL cholesterol, and triglycerides</li><li>Endocrine measurements</li><li>FT levels</li></ul><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: Bayer Schering Pharma, Berlin, Germany</p><p>Declarations of interest: employment and stock ownership from Bayer Schering Pharma AG</p>","<p>To assess the effects of testosterone administration on these subjective symptoms, which have not extensively been studied in hypogonadal men with MS</p>",<p><b>Language of publication: </b>English</p>
Gooren 2011,2011,PUB,22923513,,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled study</p><p><b>Setting/country:</b> NA</p><p><b>Dates when study was conducted:</b> NA</p>",<p><b>Inclusion criteria:</b> men aged 50 to 80 years with TT&lt; 15 nmol/L and AMS rating scale total score &gt; 36</p><p><b>Exclusion criteria:</b> NA</p><p><b>Total number of participants randomly assigned: </b>362</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 183</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 179</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>,<p><b>Group A: </b>transdermal 1% T gel 5 to 7.5 mg/day</p><p><b>Group B: </b>placebo</p><p><b>Follow-up:</b> NA</p>,"<p><b>Primary outcomes</b></p><ul><li>Change in lean body mass after 6 months</li></ul><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ul><li>Fat mass, total body mass and HRQoL</li></ul><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> NA</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To assess the efficacy of testosterone therapy in men with LOH</p>,<p><b>Language of publication: </b>English</p>
Groti 2018,2020,PUB,22923515,,"<p><b>Study design:</b> double-blind, placebo-controlled study</p><p><b>Setting/country:</b> single center/Slovenia</p><p><b>Dates when study was conducted:</b> January 2014 to March 2018</p>","<p><b>Inclusion criteria:</b> men aged &gt; 35 years, with confirmed LOH (decreased sexual interest, absent or rare morning erections, and erectile dysfunction), TT level &lt; 11 nmol/L, BMI ≥ 30 kg/m<sup>2</sup>, T2DM treated exclusively with non-insulin antidiabetic medications (metformin and sulfonylureas)</p><p><b>Exclusion criteria:</b></p><ul><li>Previously treated hypogonadism</li><li>History of current prostate or breast cancer, severe benign prostatic hyperplasia or PSA level &gt; 4.0 μg/L, severe heart failure, acute coronary event or procedure during the 6 months prior to the study, chronic obstructive lung disease, severe obstructive sleep apnea with apnea hypopnea index &gt; 30/h, and active infection</li></ul><p><b>Total number of participants randomly assigned: 55</b></p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 28</li><li>Age (mean ± SD): 58.2 ± 7.9 years</li><li>BMI (mean ± SD): 34.0 ± 4.3</li><li>Testosterone (mean ± SD): 7.24 ± 1.97 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 27</li><li>Age (mean ± SD): 62.1 ± 5.9 years</li><li>BMI (mean ± SD): 32.6 ± 3.6</li><li>Testosterone (mean ± SD): 7.96 ± 1.34 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>testosterone undecanoate (TU Nebido 1000 mg; Bayer AG) IM</p><p><b>Group B: </b>placebo (no further description)</p><p><b>Follow-up:</b> 12 months</p>,"<ul><li>Serum TT, estradiol, sex hormone binding globulin, luteinizing hormone, follicle-stimulating hormone, fasting plasma glucose, glycated hemoglobin A1c, fasting insulin, lipid profile, routine blood tests (complete blood count, electrolytes, urea, creatinine, liver tests), PSA, serum albumin</li><li>BMI</li><li>Waist circumference</li><li>Intima media thickness and plaque</li><li>Brachial artery flow-mediated dilatation, endothelium independent nitroglycerine-mediated dilatation</li></ul><p>How measured:</p><ul><li>Blood samples</li><li>Weight in kilograms divided by square of height</li><li>NR</li><li>Ultrasonography</li><li>Celermajer method</li></ul><p>Time points measured: baseline, 1 year, 2 years</p><p>Time points reported: baseline, 1 year, 2 years</p><p><b>Safety outcomes: </b>PSA, adverse event</p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: likely cumulative</p><p><b>Subgroup:</b> NA</p>",<p>NCT03792321</p>,<p>Funding sources: Bayer Pharma AG</p><p>Declarations of interest: none</p>,"<p>To assess effects of testosterone therapy on insulin resistance, visceral obesity, glycemic control, lipid abnormalities, vascular function, and morphology in obese hypogonadal men with T2DM</p>",<p><b>Language of publication: </b>English</p>
Hackett 2017,2017,PUB,22923519,,"<p><b>Study design: </b>randomized, placebo-controlled study</p><p><b>Setting/country: </b>multicenter<b>/</b>NA</p><p><b>Dates when study was conducted: </b>September 2008 to June 2012</p>","<p><b>Inclusion criteria: </b>men aged 18 to 80 years with symptoms of hypogonadism defined by the AMS together with an initial TT ≤ 12.0 nmol/L or FT ≤ 0.25 nmol/L</p><p><b>Exclusion criteria: </b>men considered too frail for TRT, previous TRT, abnormal digital rectal examination, PSA &gt; 4 ng/L, hematocrit &gt; 0.50, history of prostate cancer or other serious comorbidities</p><p><b>Total number of participants randomly assigned:</b> 199</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 97</li><li>Age (mean ± SD): 61.2 ± 10.5 years</li><li>BMI (mean ± SD): 33.0 ± 6.1</li><li>Testosterone (mean ± SD): 9.2 ± 3.1 nmol/L</li><li>IIEF-EF (mean ± SD): 13.24 ± 9.80</li><li>PSA (mean ± SD): 1.4 ± 1.4 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 102</li><li>Age (mean ± SD): 62.0 ± 9.3 years</li><li>BMI (mean ± SD): 32.4 ± 5.5</li><li>Testosterone (mean ± SD): 8.9 ± 3.8 nmol/L</li><li>IIEF-EF (mean ± SD): 11.64 ± 10.05</li><li>PSA (mean ± SD): 1.4 ± 1.2 ng/mL</li></ul>",<p><b>Group A: </b>1000 mg TU IM</p><p><b>Group B: </b>placebo injection</p><p><b>Follow-up:</b> 30 weeks</p>,"<p><b>Primary outcomes</b></p><ul><li>Change in glycemic control</li></ul><p>How measured: HbA1c</p><p>Time points measured: screening, 6, 18, 30 weeks</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ol><li>Erectile function</li><li>Sexual desire</li></ol><p>How measured:</p><ol><li>IIEF-EF</li><li>Sexual desire domain of IIEF</li></ol><p>Time points measured: screening, 6, 18, 30 weeks</p><p>Time points reported: screening, 6, 18, 30 weeks</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b></p><ul><li>Hypogonadism: mild (TT: 8.1 to 12 nmol/L or FT: 0.181 to 0.25 nmol/L), severe (TT: ≤ 8.0 nmol/L and FT: ≤ 0.18 nmol/L)</li></ul>",<p>NA</p>,"<p>Funding sources: Bayer</p><p>Declarations of interest: grant from Bayer, honoraria for serving as a speaker for Bayer, Besins, or European Society for Sexual Medicine</p>",<p>To assess the impact of TRT on men with T2DM</p>,<p><b>Language of publication: </b>English</p>
Hakobyan 2013,2013,PUB,22923528,,"<p><b>Study design: </b>randomized, placebo-controlled, double-blind, parallel-group study</p><p><b>Setting/country: </b>multicenter/NA</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria: </b>men with arteriogenic ED as evaluated by dynamic color duplex ultrasound studies, normal sexual desire but testosterone and FT in the lower quartile of normal range (low-normal), not responding to tadalafil treatment (10 mg) on 6 consecutive attempts</p><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>NA</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: NA</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: NA</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>5 mg/day of 1% T gel + as adjunctive therapy to 10 mg tadalafil</p><p><b>Group B: </b>5 mg placebo gel as adjunctive therapy to 10 mg tadalafil</p><p><b>Follow-up: </b>12 weeks</p>,<p><b>Primary outcomes</b></p><ul><li>Measurement of flow parameters</li></ul><p>How measured: dynamic color duplex ultrasound</p><p>Time points measured: before and after 1 month of therapy</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ol><li>Erectile function</li><li>Sexual quality of life</li></ol><p>How measured:&nbsp;</p><ol><li>Total and erectile function of IIEF</li><li>GAQ</li></ol><p>Time points measured: before and after 1 month of therapy</p><p>Time points reported: </p><ol><li>4 weeks</li><li>NA</li></ol><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>,<p>NA</p>,<p>Funding sources: none</p><p>Declarations of interest: NR</p>,<p>To compare the efficacy of testosterone gel (T gel) versus placebo as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction who do not respond to tadalafil alone</p>,<p><b>Language of publication: </b>English</p>
Haren 2005,2005,PUB,22923530,,"<p><b>Study design: </b>randomized, double-blind</p><p><b>Setting/country: </b>NA</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Aged 60 years or older</li><li>At least 2 symptoms on the ADAM questionnaire</li><li>FT index between 0.3 and 0.5</li><li>TT greater than 8nmol/L</li></ul><p><b>Exclusion criteria:</b></p><ul><li>History or presence of prostate cancer or a PSA &gt; 5 ng/mL</li><li>Score of greater than 20 on the IPSS</li><li>Suggestion of significant urinary obstruction</li><li>Abnormal prostate on digital rectal examination</li><li>History of testicular, liver or renal disease, diabetes mellitus, cardiac failure, a score of greater than 15 on the Geriatric Depression Scale, significant joint pain, prior use of androgen, bisphosphonates, oral, intravenous or intraarticular glucocorticoid within the preceding 6 months or hematocrit greater than 50%</li></ul><p><b>Total number of participants randomly assigned: </b>76</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 39</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 37</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>TU (Andriol®, Organon, Oss, The Netherlands) 80 mg orally, twice daily</p><p><b>Group B:</b> placebo</p><p><b>Follow-up: </b>12 months</p>","<p><b>Primary outcomes</b></p><ul><li>Symptom</li></ul><p>How measured: St Louis University ADAM symptoms</p><p>Time points measured: screening, 6 and 12 months</p><p>Time points reported: baseline, 12 months</p><p><b>Secondary outcomes</b></p><ul><li>Blood test</li></ul><p>How measured: TT, calculated bioavailable testosterone</p><p>Time points measured: baseline, 1, 3, 6, 12 months</p><p>Time points reported: baseline, 12&nbsp;months</p><p><b>Safety outcomes</b></p><p>How measured: recorded</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b></p><ul><li>Bioavailable testosterone &lt; 3.1, bioavailable testosterone ≥ 3.1</li></ul>",<p>NA</p>,<p>Funding sources: Organon Pty Ltd and the University of Adelaide</p><p>Declarations of interest: Organon Pty Ltd </p>,"<p>To assess the effect of 12 months of treatment with oral TU on symptoms of testosterone deficiency, in elderly men with 2 or more symptoms on the St Louis University ADAM questionnaire and a testosterone level in the low–normal range relative to young men</p>",<p><b>Language of publication: </b>English</p>
Hisasue 2015,2015,PUB,22923532,,"<p><b>Study design: </b>double-blind, placebo-controlled clinical trial</p><p><b>Setting/country: </b>NA</p><p><b>Dates when study was conducted: </b>NA</p>",<p><b>Inclusion criteria: </b>men with LOH symptoms (TT &lt; 450 ng/dL and total AMS scores ≥ 27) and ≥ 40 years</p><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>62</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 31</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 31</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>,<p><b>Group A: </b>25 mg of 2.5% testosterone gel was administered once every morning</p><p><b>Group B: </b>gel without testosterone was administered once every morning</p><p><b>Follow-up: </b>12 weeks</p>,"<ol><li>Erectile function</li><li>LUTS</li><li>Self-rated questionnaires</li><li>Blood sample</li><li>Physical measurement</li></ol><p>How measured:&nbsp;</p><ol><li>SHIM</li><li>IPSS</li><li>EHS, Self-rating Depression Scale, State-Trait Anxiety Inventory, Athens Insomnia Scale</li></ol><p>Time points measured: baseline and at week 12</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To develop a new formulation of testosterone gel (2.5%) and carry out a randomized controlled clinical trial and assess its efficacy for LUTS and sleeping status as well as LOH</p>,<p><b>Language of publication: </b>English</p>
Ho 2012,2012,PUB,22923534,,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled trial</p><p><b>Setting/country: </b>single center/Malaysia</p><p><b>Dates when study was conducted: </b>May 2008 to February 2010</p>","<p><b>Inclusion criteria:</b></p><ul><li>Age 40 to 70 years</li><li>At least 'mild' symptoms for all 3 AMS domains (scores of ≥ 9 in the somatic, ≥ 6 in the psychological, and ≥ 6 in the sexual domain) or total AMS scores ≥ 27</li><li>Early morning TT level &lt; 12 nmol/L on 2 occasions</li><li>PSA level of &lt; 4 ng/mL</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Uncontrolled diabetes mellitus (HbA1c &gt; 8%)</li><li>Clinical hypothyroidism or hyperthyroidism; hematocrit &gt; 55%</li><li>Known prostate cancer</li><li>Androgen-dependent carcinoma of the male mammary gland</li><li>Past or present liver tumors</li><li>Other significant medical conditions (American Society of Anesthetists score &gt; 3) or psychological conditions (psychosis, schizophrenia, or manic depression)</li><li>Clinically diagnosed sleep apnea</li><li>Medication known to interfere with testosterone metabolism, had hypersensitivity to the active substance or excipients of the study medication, testosterone treatment (transdermal, oral, or IM) within the previous 6 months or testosterone implants within the previous 12 months</li></ul><p><b>Total number of participants randomly assigned: </b>120</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 60</li><li>Age (mean ± SD): 53.4 ± 7.4 years</li><li>BMI (mean ± SD): 30.4 ± 5.2 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 8.9 ± 2.0 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 60</li><li>Age (mean ± SD): 53 ± 8.2 years</li><li>BMI (mean ± SD): 28.2 ± 4.5 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 9.1 ± 1.8 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>testosterone undecanoate in 4 mL of castor oil 1000 mg, 30 injections</p><p><b>Group B: </b>placebo (castor oil only)</p><p><b>Follow-up: </b>48 weeks</p>","<p><b>Primary outcomes</b></p><ul><li>Sexual quality of life</li></ul><p>How measured: AMS score</p><p>Time points measured: screening, 18 and 48 weeks</p><p>Time points reported: screening, 48 weeks</p><p><b>Secondary outcomes</b></p><ol><li>Anthropometric changes</li><li>LUTS</li><li>QoL</li><li>Laboratory blood results</li></ol><p>How measured:</p><ol><li>Clinical assessment</li><li>IPSS</li><li>SF-12</li><li>NA</li></ol><p>Time points measured:</p><ol><li>Baseline, 6, 18, 30, 42, 48 weeks</li><li>Baseline, 18, 48 weeks</li><li>Baseline, 18, 48 weeks</li><li>Baseline, 18, 48 weeks</li></ol><p>Time points reported:</p><ol><li>NA</li><li>NA</li><li>NA</li><li>Baseline, 18, 48 weeks</li></ol><p><b>Safety outcomes</b></p><p>How measured: clinical assessment</p><p>Time points measured: baseline, 18, 48 weeks</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: Bayer Schering Pharma</p><p>Declarations of interest: NR</p>,<p>To evaluate the effect of IM injection of testosterone undecanoate 1000 mg over 12 months on the AMS scale in men with testosterone deficiency syndrome</p>,<p><b>Language of publication: </b>English</p>
Kunelius 2002,2002,PUB,22923540,,"<p><b>Study design: </b>prospective, randomized, double-blind study</p><p><b>Setting/country: </b>single center/Finland</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Rarefaction of nocturnal penile tumescence (once or less per week; frequency of early morning erections together with libido are known to have correlation with serum androgen levels)</li><li>At least one of the following andropause symptoms: decreased libido, erectile dysfunction, urinary disorders, asthenia, or depressive mood.</li><li>TT ≤ 15 nmol/L</li><li>SHBG ≥ 30 nmol/L</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Significant cardiovascular disease, abnormal lipid profile (total cholesterol 7.5 mmol/L and/or triglycerides 1.7 mmol/L), alcohol abuse, and uncured cancer</li><li>With neurological impotence, major depression, or other psychiatric diseases</li><li>Those taking hormones or drugs affecting sexual function, lipid/hormone metabolism, or hematological parameters</li></ul><p><b>Total number of participants randomly assigned: </b>120</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 60</li><li>Age (mean ± SD): 58.3 ± 4.8 years</li><li>BMI (mean ± SD): 25.7 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): NA</li><li>Ability to maintain erection during intercourse (1, always; 2, in 75% of intercourse; 3, in 50%; 4, in less than 25%; 5, in less than 10%; 6, never; mean ± SD): 2.26 ± 1.41</li><li>PSA (mean ± SD): 1.6 ± 1.6 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 60</li><li>Age (mean ± SD): 58.6 ± 5.7 years</li><li>BMI (mean ± SD): 26.1 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): NA</li><li>Ability to maintain erection during intercourse (1, always; 2, in 75% of intercourse; 3, in 50%; 4, in less than 25%; 5, in less than 10%; 6, never; mean ± SD): 2.53 ± 1.44</li><li>PSA (mean ± SD): 1.5 ± 1.2 ng/mL</li></ul>",<p><b>Group A: </b>DHT gel 125&nbsp;mg/187.5&nbsp;mg/250&nbsp;mg</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>6 months</p>,"<p><b>Primary outcomes</b></p><ul><li>Sexual function</li></ul><p>How measured: modified IIEF</p><p>Time points measured: baseline, 3, 6 months</p><p>Time points reported: baseline, 3, 6 months</p><p><b>Secondary outcomes</b></p><ol><li>Well-being</li><li>Urinary symptoms</li><li>Blood test</li></ol><p>How measured:</p><ol><li>Psychological General Well-Being scale</li><li>IPSS</li><li>T, estradiol, FSH, SHBG</li></ol><p>Time points measured:</p><ol><li>Baseline, 1, 3, 6 months</li><li>NA</li><li>Baseline, 6 months</li></ol><p>Time points reported:</p><ol><li>NA</li><li>Baseline, 1, 3, 6 months</li><li>Baseline, 6 months</li></ol><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: NR</p><p>Declarations of interest: Support from Sigrid Juselius Foundation, the Academy of Finland, and Laboratories Besins Iscovesco</p>","<p>To assess the efficacy and safety of DHT in the treatment of andropause symptoms, we administered DHT gel or placebo transdermally to 120 men for 6 months</p>",<p><b>Language of publication: </b>English</p>
Legros 2009,2009,PUB,22923542,,"<p><b>Study design: </b>randomized, placebo-controlled study</p><p><b>Setting/country: </b>multicenter/Europe</p><p><b>Dates when study was conducted: </b>November 2001 to July 2004</p>","<p><b>Inclusion criteria:</b></p><ul><li>At least 50 years of age</li><li>BMI between 18 and 34 kg/m<sup>2</sup></li><li>Symptoms of androgen deficiency (as indicated by a positive score on the ADAM questionnaire)</li><li>Calculated FT &gt; 0.26 nmol/L</li></ul><p><b>Exclusion criteria:</b></p><ul><li>History or present diagnosis of breast or prostate cancer</li><li>Any clinically significant abnormal finding on physical examination, including the prostate</li><li>LUTS (IPSS &gt;14)</li><li>PSA level &gt; 4 ng/mL at screening; cause of androgen deficiency other than aging</li><li>Treatment with androgens or anabolic steroids within the last 2 years</li><li>Hyperprolactinemia or treatment with prolactin-lowering drugs</li><li>History of chronic and other diseases</li><li>Participants who used medication that would interfere with the efficacy and safety objectives of the trial or who were not stabilized on any concomitant medication (continuous use) during at least 3 months prior to randomization</li></ul><p><b>Total number of participants randomly assigned: </b>316</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 78</li><li>Age (mean ± SD): 59.5 ± 6.5 years</li><li>BMI (mean ± SD): 27.3 ± 3.4 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 82</li><li>Age (mean ± SD): 58.4 ± 5.7 years</li><li>BMI (mean ± SD): 27.5 ± 3.5 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group C</b></p><ul><li>Number of all participants randomly assigned: 77</li><li>Age (mean ± SD): 58.6 ± 5.7 years</li><li>BMI (mean ± SD): 26.8 ± 3.5 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group D</b></p><ul><li>Number of all participants randomly assigned: 79</li><li>Age (mean ± SD): 58.4 ± 5.5 years</li><li>BMI (mean ± SD): 27.4 ± 3.0 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>TU 80&nbsp;mg (80 mg once daily)</p><p><b>Group B: </b>TU 160&nbsp;mg (80 mg twice daily)</p><p><b>Group C: </b>TU 240&nbsp;mg (80 mg thrice daily)</p><p><b>Group D: </b>placebo</p><p><b>Follow-up: </b>12 months</p>,"<p><b>Outcomes</b></p><ul><li>Erectile function</li></ul><p>How measured: DISF-SR</p><p>Time points measured: at baseline, month 3, 6, and 12</p><p>Time points reported: NA</p><p><b>Secondary Outcomes</b></p><ol><li>Sexual quality of life</li><li>HRQoL</li></ol><p>How measured:</p><ol><li>AMS</li><li>SF-36</li></ol><p>Time points measured:&nbsp;</p><ol><li>Baseline, 1, 3, 6, 9, 12 months</li><li>Baseline, 3, 6, 12 months</li></ol><p><b>Safety outcomes</b></p><ol><li>Physical examination</li><li>Lower urinary tract symptoms</li><li>Blood test</li></ol><p>How measured:</p><ol><li>NA</li><li>IPSS</li><li>NA</li></ol><p>Time points measured:</p><ol><li>Baseline, 6, 12 months</li><li>Baseline, 6, 12 months</li><li>Baseline, 1, 3, 6, 9, 12 months</li></ol><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NTC00434824</p>,"<p>Funding sources: Schering-Plough and Organon International (now Merck, Sharp &amp; Dohme Corp)</p><p>Declarations of interest: none</p>",<p>To investigate the effects of oral TU on symptoms associated with LOH</p>,<p><b>Language of publication: </b>English</p>
Li 2013,2013,PUB,22923547,,<p><b>Study design: </b>randomized study</p><p><b>Setting/country: </b>single center/China</p><p><b>Dates when study was conducted: </b>NA</p>,"<p><b>Inclusion criteria:</b></p><ul><li>Married men with living spouse</li><li>Men with LOH symptoms</li><li>Physical symptoms plus vasomotor symptoms total score ≥ 5 points; or mental and psychological symptoms ≥ 4 points; or symptoms of sexual dysfunction ≥ 8 points</li><li>IIEF-5 score &lt; 21 points and course 3; more than a month</li><li>Serum TT &lt; 12.0 nmol/L or FT &lt; 0.225 nmol/L</li><li>Informed consent</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Benign prostatic hyperplasia with dysuria</li><li>Already suffering from prostate cancer or breast cancer</li><li>Severe breathing suspension syndrome</li><li>Polycythemia</li><li>Severe mental abnormalities (including severe depression or schizophrenia)</li><li>Those with obvious genital malformations</li><li>With hereditary pigmented visual network</li><li>History of membranous inflammation, alcoholism, and severe blood and kidney or liver disease</li><li>Recent use of nitrate drugs or other similar drugs</li><li>Stroke or myocardial infarction in the past 6 months&nbsp;</li><li>Infarct history</li><li>Those with a history of malignant hypertension or hypotension</li><li>Allergic to tadalafil and testosterone undecanoate</li><li>Serum abnormal PSA</li><li>Taking other related hormone drugs within 6 months</li></ul><p><b>Total number of participants randomly assigned: </b>90</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 45</li><li>Age (mean ± SD): 54.5 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 10.10 ± 1.20 nmol/L</li><li>IIEF-5 (mean ± SD): 15.7 ± 3.9</li><li>PSA (mean ± SD): 2.3 ± 1.2 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 45</li><li>Age (mean ± SD): 52.5 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 10.2 ± 1.1 nmol/L</li><li>IIEF-5 (mean ± SD): 15.6 ± 3.8</li><li>PSA (mean ± SD): 2.3 ± 1.3 ng/mL</li></ul>","<p><b>Group A: </b>testosterone undecanoate 40&nbsp;mg, 2 times/day (morning/night) + tadalafil (same dose of control group)</p><p><b>Group B: </b>tadalafil (American Lilly) 5 mg, 1 time/day</p><p><b>Follow-up: </b>12 weeks</p>","<ol><li>Erectile function</li><li>Sexual quality of life</li><li>Prostate-related events</li><li>LOH symptom score</li><li>Blood test</li></ol><p>How measured:&nbsp;</p><ol><li>IIEF-5</li><li>SEP</li><li>PSA, transrectal B-ultrasound measurement of prostate volume</li><li>LOH symptom score</li><li>T, FT</li></ol><p>Time points measured: before and after treatment</p><p>Time points reported: before and after treatment</p><p><b>Safety outcomes</b></p><p>How measured: blood routine, urine routine, liver and kidney</p><p>Time points measured: before and after treatment</p><p>Time points reported: before and after treatment</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To observe the clinical effect of low-dose testosterone undecanoate capsules combined with tadalafil on LOH accompanied by ED</p>,<p><b>Language of publication: </b>Chinese</p>
Lincoff 2023,,PUB,24007906,,"<p><b>Study design:</b> phase 4, randomized, double-blind, placebo-controlled, non-inferiority, event-driven trial</p><p><b>Setting/country:</b> multicenter/USA</p><p><b>Dates when study was conducted:</b> May 2018 to January 2023</p>","<p><b>Inclusion criteria: </b>men aged 45 to 80 years with pre-existing cardiovascular disease or an elevated cardiovascular risk; reported one or more symptoms of hypogonadism, including decreased sexual desire or libido, decreased spontaneous erections, fatigue or decreased energy, low or depressed mood, loss of axillary or pubic body hair or decreased frequency of shaving, or hot flashes; and had 2 fasting serum testosterone levels of less than 300 ng per dL (10.4 nmol per L)</p><p><b>Exclusion criteria:&nbsp;</b></p><ul><li>Men with congenital or acquired hypogonadism for whom long-term therapy with placebo would not be medically appropriate (e.g. men with 2 testosterone levels &lt; 100 ng/dL)</li><li>Men with conditions that constitute a contraindication for testosterone therapy, including unstable medical conditions that might compromise the participant’s safety or render it difficult or unsafe to apply transdermal testosterone gel (if they had history of prostate or breast cancer; undiagnosed prostate nodule or prostate induration; severe LUTS (IPSS &gt; 19); screening PSA &gt; 3 ng/mL (or &gt; 1.5 ng/mL if they were taking a 5-alpha reductase inhibitor); erythrocytosis; thrombophilia, unprovoked deep vein thrombosis or pulmonary embolism; hematocrit &gt; 50%; uncontrolled heart failure; untreated severe obstructive sleep apnea; severe or end-stage chronic kidney disease (estimated glomerular filtration rate &lt; 30 mL/min/1.73 m<sup>2</sup>); or body mass index &gt; 50 kg/m<sup>2</sup>)</li><li>Men within the first 4 months after documented myocardial infarction, stroke, percutaneous coronary angioplasty, coronary artery bypass graft surgery, unstable angina; or procedures to treat critical limb ischemia</li><li>Men who during the preceding 6 months had received testosterone replacement, clomiphene, anabolic steroids, compounded or over the counter androgenic steroid derivatives and dehydroepiandrosterone, including investigational products that may affect the reproductive hormonal system</li></ul><p><b>Total number of participants randomly assigned: </b>5204</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 2601</li><li>Age (mean ± SD): 63.3 ± 7.9 years</li><li>BMI (mean ± SD): 35.0 ± 5.7</li><li>Testosterone (median, IQR): 7.9 (6.6 to 8.9) nmol/L</li><li>IIEF-5 (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 2603</li><li>Age (mean ± SD): 63.3 ± 7.9 years</li><li>BMI (mean ± SD): 34.8 ± 6.0</li><li>Testosterone (median, IQR): 7.9 (6.5 to 8.9) nmol/L</li><li>IIEF-5 (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>daily transdermal 1.62% testosterone gel</p><p><b>Group B:</b> placebo</p><p><b>Follow-up: </b>12 months</p>,"<p><b>Primary outcome</b></p><ul><li>Time from randomization to first occurrence of any component of the major adverse cardiovascular event composite of nonfatal myocardial infarction, nonfatal stroke, or death due to cardiovascular causes</li></ul><p>How measured: NR</p><p>Time points measured: first occurrence of outcome</p><p>Time points reported: cumulative incidence</p><p><b>Secondary outcomes</b></p><ol><li>Time to first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal stroke, death due to cardiovascular causes, or coronary revascularization</li><li>Incidence of high-grade prostate cancer</li></ol><p>How measured:&nbsp;</p><ol><li>NR</li><li>Pathologically confirmed prostate cancer with Gleason score 4 + 3 or higher</li></ol><p>Time points measured: first occurrence of outcome</p><p>Time points reported: cumulative incidence</p><p><b>Other outcomes</b></p><ol><li>All-cause mortality, hospitalization, or urgent visit for heart failure, venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, venous thromboembolism; or peripheral arterial revascularization</li><li>Prostate biopsy; any prostate cancer; acute urinary retention; starting pharmacologic treatment for LUTS; and invasive prostate surgical procedures (e.g. prostatectomy, transurethral prostate resection, brachytherapy or other prostate surgical procedure for benign prostatic hyperplasia)</li><li>Improvement in sexual activity/remission of depression/reduction in incidence of clinical fractures/correction of anemia/reduction in progression from prediabetes to diabetes</li></ol><p>How measured: NR</p><p>Time points measured:</p><ol><li>First occurrence of outcome</li><li>First occurrence of outcome</li><li>NR</li></ol><p>Time points reported:&nbsp;</p><ol><li>Cumulative incidence</li><li>Cumulative incidence</li><li>NR</li></ol><p><b>Subgroup:</b> none</p>",<p>NCT03518034</p>,"<p><b>Funding sources:</b> AbbVie</p><p><b>Declarations of interest:</b> lead author reported receiving research grants from the government, pharmaceutical companies, and Brigham and Women’s Hospital</p>",<p>To determine the effects of testosterone-replacement therapy on the incidence of major adverse cardiac events among middle-aged and older men with hypogonadism and either pre-existing or a high risk of cardiovascular disease</p>,<p><b>Language of publication: </b>Russian</p>
Lu 2003,2003,PUB,22923549,,<p><b>Study design: </b>prospective randomized controlled study</p><p><b>Setting/country: </b>single center/China</p><p><b>Dates when study was conducted: </b>NA</p>,"<p><b>Inclusion criteria: </b>patients aged 50 to 70 years who have reliable, fixed sexual partners</p><p><b>Exclusion criteria: </b>symptomatic benign prostatic hyperplasia and prostate cancer</p><p><b>Total number of participants randomly assigned: </b>60</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group C</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>Viagra + vitamin E + Andriol 120 mg/day</p><p><b>Group B: </b>Viagra + vitamin E 60 mg/day, 3 times per oral administration</p><p><b>Group C: </b>Viagra single oral administration 0.5 to 1 hour before sexual life</p><p><b>Follow-up: </b>3 months</p>","<ol><li>Erectile function</li><li>Symptom</li><li>Endocrine and biochemical tests</li><li>Physical examination</li></ol><p>How measured: written above</p><ol><li>IIEF score</li><li>PADAM score</li><li>Sex hormone, blood PSA, hematuria, liver and kidney function</li><li>Weight, hair distribution and BP, pulse and other changes</li></ol><p>Time points measured: before and after treatment, 1 month, 2 months, and 3 months after treatment</p><p>Time points reported: before and after treatment, 1 month, 2 months, and 3 months after treatment</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: before and after treatment</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>NR</p>,<p><b>Language of publication: </b>Chinese</p>
Lunglmayr 1980,1980,PUB,22923551,,"<p><b>Study design: </b>double-blind, placebo-controlled trial</p><p><b>Setting/country: </b>NA</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Men who had suffered from non-partner-related erectile impotence for more than 1 year</li><li>Deterioration of state of mind (in the sense of the so-called 'climacterium virile')</li><li>At least 6 of the 32 items from at least 3 different classes were correct and the disorders had only occurred in the last 2 years</li></ul><p><b>Exclusion criteria: </b>organic causes like neuropathia, hypertension, DM, changes in the genital system, or psychosis</p><p><b>Total number of participants randomly assigned: </b>17</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 8</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 11.5 ± 5.5 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 9</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 9.9 ± 5.8 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>25&nbsp;mg mesterolone 3 times daily</p><p><b>Group B: </b>placebo<b> </b>3 tablets daily</p><p><b>Follow-up: </b>8 weeks</p>,"<ol><li>Psychological procedures</li><li>Clinical procedures</li><li>Endocrinological procedures</li></ol><p>How measured:</p><ol><li>VELA questionnaire (Fahrenberg), Freiburg Personality Inventory, flicker fusion frequency determination, reaction time, Pauli calculation test</li><li>NA</li><li>Testosterone, plasma LH concentration</li></ol><p>Time points measured:</p><ol><li>Before the first medication intake and 4 and 8 weeks later</li><li>NA</li><li>Before and after the end of the test</li></ol><p>Time points reported:</p><ol><li>Before the first medication intake and 4 and 8 weeks later</li><li>NA</li><li>Before and after the end of the experimental period</li></ol><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>NR</p>,<p><b>Language of publication: </b>German</p>
Maggi 2016,2016,PUB,22923553,,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled trial</p><p><b>Setting/country: </b>multicenter/NA</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>At least 18 years of age</li><li>TT level lower than 300 ng/dL (10.4 nmol/L) at both visits 1 and 2</li><li>At least one symptom of T deficiency (decreased energy or decreased sexual drive)</li><li>PSA level lower than 4 ng/mL</li><li>No use of oral or topical testosterone therapy within 14 days before visit 1</li><li>Stable doses of lipid-lowering medications, insulin, antidepressants, anxiolytics, or therapy for benign prostatic hyperplasia for at least 3 months before visit 1</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Use of long-acting intramuscular testosterone undecanoate or testosterone pellets 6 months before screening</li><li>BMI &gt; 37 kg/m<sup>2</sup></li><li>Severe LUTS and significant prostate enlargement as determined by the investigator</li><li>Prolactin &gt; 30 ng/mL</li><li>HbA1c &gt; 11%</li><li>Hematocrit levels &gt; at least 50%</li><li>Dermatologic conditions in the underarm area that would interfere with testosterone absorption or be exacerbated by topical testosterone replacement therapy</li><li>Current treatment with chemotherapy or antiandrogens, long-term use of systemic glucocorticoids, use of anabolic steroids or estrogenizing agents within 12 months before visit 1</li><li>History of frequent opioid use, luteinizing hormone-releasing hormone antagonist or agonist treatment, clomiphene or other antiestrogen treatment, and use of finasteride, dutasteride, warfarin, phenprocoumon, or dopamine receptor agonists</li><li>History of central nervous system injuries or disease, malignant hypertension, unstable angina or coronary artery disease, liver disease, renal disease, or human immunodeficiency virus infection, or clinical suspicion or history of prostate cancer</li></ul><p><b>Total number of participants randomly assigned:</b> 715</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 358</li><li>Age (mean ± SD): 54.7 ± 10.58 years</li><li>BMI (mean ± SD): 30.3 ± 4.06 kg/m²</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 357</li><li>Age (mean ± SD): 55.9 ± 11.35 years</li><li>BMI (mean ± SD): 30.9 ± 4.21 kg/m²</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>testosterone solution 60 mg once daily + dosage adjustment (30~120 mg)</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>12 weeks</p>,"<ol><li>Erectile function</li><li>Ejaculatory function score</li></ol><p>How measured:</p><ol><li>IIEF-EF</li><li>MSHQ-EjD-SF</li></ol><p>Time points measured: baseline, 12 weeks</p><p>Time points reported: baseline, 12 weeks</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: Eli Lilly and Company</p><p>Declarations of interest: honoraria for serving as consultant and speaker for Bayer, Eli Lilly, Menarini, Prostrakan, and Intercept, grant, employment and stock ownership from Eli Lilly and Company</p>",<p>To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal men</p>,<p><b>Language of publication: </b>English</p>
Merza 2006,2006,PUB,22923556,,"<p><b>Study design: </b>double-blind, placebo-controlled study</p><p><b>Setting/country: </b>NA</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Men over 40 years presenting to the Sheffield male sexual dysfunction clinic were screened with measurement of serum TT (sample collected at 09:00 hours)</li><li>Serum total T &lt; 10 nmol/L and/or a FAI &lt; 30%&nbsp;</li><li>Absence of known prostate or breast cancer, prostatic hypertrophy, raised serum PSA (&gt; 2.5 μg/L), uncontrolled hypertension, diabetes mellitus, uncontrolled cardiac disease, renal failure (creatinine &gt; 150 μmol/L), liver disease, polycythemia (hematocrit &gt; 50%), history of aggressive behavior, alcohol or drug abuse, anticoagulant therapy, or testosterone replacement</li></ul><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>39</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 19</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>","<p><b>Group A: </b>Testoderm TTS 328 mg testosterone, delivering 5 mg/day</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>6 months</p>","<p><b>Primary outcomes</b></p><ul><li>Bone turnover</li></ul><p>How measured: uNTX, iFDPD, OC, bone ALP</p><p>Time points measured: baseline, 1, 3, 6, and 12</p><p>Time points reported: baseline, 1, 3, 6, and 12</p><p><b>Secondary outcomes</b></p><ol><li>Body composition</li><li>Hormone</li><li>QoL</li></ol><p>How measured:</p><ol><li>DEXA</li><li>Total T, estradiol, SHBG, LH, FSH</li><li>Male Erectile Dysfunction Quality of Life questionnaire, General Well-Being Index</li></ol><p>Time points measured:</p><ol><li>Baseline, 6, 12 months</li><li>Baseline, 1, 6, 12 months</li><li>Baseline, 6, 12 months</li></ol><p>Time points reported:</p><ol><li>Baseline, 6, 12 months</li><li>6 months</li><li>6 months</li></ol><p><b>Safety outcomes</b></p><p>How measured: physical examination, laboratory test</p><p>Time points measured: screening, baseline, 1, 3, 6, 9, 12 months</p><p>Time points reported: 6 months</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: Ferring Pharmaceuticals Limited, UK</p><p>Declarations of interest: NR</p>","<p>Patients presenting with sexual dysfunction and borderline low testosterone will show an improvement in measures of skeletal function, body composition, and QoL when treated with testosterone</p>",<p><b>Language of publication: </b>English</p>
Morales 2009,2009,PUB,22923558,,"<p><b>Study design:</b> placebo-controlled, randomized, double-blind study</p><p><b>Setting/country:</b> multicenter/Canada</p><p><b>Dates when study was conducted:</b> December 2006 to September 2007</p>","<p><b>Inclusion criteria:</b></p><ul><li>Men 45 to 70 years of age with a primary complaint of sexual dysfunction</li><li>Clinical picture compatible with T deficiency syndrome</li><li>History of sexual dysfunction for &gt; 3 months with IIEF scores of &lt; 25 on questions 1 to 5 and 15</li><li>History of hypoactive sexual desire disorder for &gt; 3 months with scores of &gt; 6 for questions 11 and 12 of the IIEF and serum total testosterone levels &lt; 12 nmol/L and DHEAS of &lt; 3.5 μmol/L</li></ul><p><b>Exclusion criteria: </b>men who have contraindication for the use of androgens, including a history of prostate cancer, PSA levels &gt; 4 ng/L, or a history of substance abuse within 2 years</p><p><b>Total number of participants randomly assigned: </b>58</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 29</li><li>Age (mean ± SD): 59.0 ± 10.6 years</li><li>BMI (mean ± SD): 31.3 ± 5.4 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 10.2 ± 4.9 nmol/L</li><li>Total IIEF (mean ± SD): 33.9 ± 17.1</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 29</li><li>Age (mean ± SD): 60.2 ± 9.6 years</li><li>BMI (mean ± SD): 29.7 ± 4.4 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 10.0 ± 5.5 nmol/L</li><li>Total IIEF (mean ± SD): 30.5 ± 19.3</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>oral testosterone undecanoate 80 mg twice daily</p><p><b>Group B: </b>placebo (dose and frequency were not provided)</p><p><b>Run-in period: </b>none</p><p><b>Follow-up: </b>4 months</p>,"<p><br><b>Primary outcomes</b></p><ol><li>Erectile function</li><li>Sexual quality of life</li></ol><p>How measured:</p><ol><li>Erectile and desire domains of the IIEF</li><li>AMS</li></ol><p>Time points measured: baseline, 16 weeks</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ul><li>Responder rates based upon questionnaires</li></ul><p>How measured: ADAM questionnaire, GAQ</p><p>Time points measured: baseline, 16 weeks</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: 16 weeks</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NCT00202163</p>,<p>Funding sources: Organon Canada and Paladin Laboratories</p><p>Declarations of interest: NR</p>,"<p>Supplemental administration of androgens has been advocated for men with sexual dysfunction and hypoandrogenism. The preponderance of evidence indicates that most delivery forms of T are effective but the role of DHEA is controversial. A placebo-controlled, randomized trial of oral androgen (T versus DHEA) supplementation was carried out to determine its efficacy</p>",<p><b>Language of publication: </b>English</p>
Paduch 2015,2015,PUB,22923560,NCT01419236,"<p><b>Study design: </b>randomized controlled study</p><p><b>Setting/country: </b>multicenter/USA, Canada, Mexico</p><p><b>Dates when study was conducted: </b>August 2011 to December 2013</p>","<p><b>Inclusion criteria:</b></p><ul><li>Community-dwelling, sexually active men 26 years of age and older</li><li>Total T levels &lt; 300 ng/dL (10.41 nmol/L) on 2 occasions</li><li>One or more of the following symptoms: delayed ejaculation, anejaculation, decreased force of ejaculation, or decreased ejaculate volume</li><li>PSA levels &lt; 4 ng/mL and willingness to masturbate</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Men with premature ejaculation, severe erectile dysfunction, and diseases of the pelvis</li><li>Medications that could potentially impact ejaculatory function</li><li>History of prostate or breast cancer</li><li>Hematocrit ≥ 50%</li><li>Significant LUTS</li><li>Current T therapy</li><li>Dermatological conditions affecting axillae</li><li>BMI &gt; 35 kg/m²</li></ul><p><b>Total number of participants randomly assigned: </b>76</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 36</li><li>Age (mean ± SD): 48.4 ± 9.8 years</li><li>BMI (mean ± SD): 30.6 ± 3.05 kg/m²</li><li>Testosterone (mean ± SD): 7.4 ± 1.9 nmol/L</li><li>IIEF-EF (mean ± SD): 18.9 ± 6.4</li><li>PSA (mean ± SD): 0.92 ± 0.75 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 40</li><li>Age (mean ± SD): 52.7 ± 9.3 years</li><li>BMI (mean ± SD): 30.8 ± 3.16 kg/m²</li><li>Testosterone (mean ± SD): 7.7 ± 1.8 nmol/L</li><li>IIEF-EF (mean ± SD): 18.9 ± 6.3</li><li>PSA (mean ± SD): 0.86 ± 0.55 ng/mL</li></ul>",<p><b>Group A: </b>60 mg daily T solution 2% daily</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>16 weeks</p>,"<p><b>Primary outcomes</b></p><ul><li>Ejaculatory dysfunction</li></ul><p>How measured: MSHQ-EjD-SF</p><p>Time points measured: NA</p><p>Time points reported: baseline, 4, 8, 12, 16 weeks</p><p><b>Secondary outcomes</b></p><ol><li>Ejaculate volume</li><li>Orgasmic function</li><li>Sexual activity</li><li>MSHQ-EjD-SF bother/satisfaction score (Q4)</li></ol><p>How measured:</p><ol><li>Measured after liquefaction</li><li>IIEF Q9 and Q10</li><li>Based on sexual activity log</li><li>MSHQ-EjD-SF bother/satisfaction score (Q4)</li></ol><p>Time points measured: NA</p><p>Time points reported: baseline, 16 weeks</p><p><b>Safety outcomes</b></p><p>How measured: EKG; cardiovascular events of stroke, myocardial infarction, unstable angina requiring hospitalization, or death</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> MSHQ-EjD-SF score in men presenting only with anejaculation or delayed ejaculation</p>",<p>NCT01419236</p>,"<p>Funding sources: Eli Lilly and Company</p><p>Declarations of interest: trial support, employment, and stock ownership from Eli Lilly and Company, and grants from Abbvie</p>",<p>To evaluate the efficacy of T replacement in androgen-deficient men with ejaculatory dysfunction</p>,<p><b>Language of publication: </b>English</p>
Rao 2023,2023,PUB,24007911,,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled trial</p><p><b>Setting/country: </b>NA/UK</p><p><b>Dates when study was conducted: </b>NA</p>","<p><b>Inclusion criteria: </b>hypogonadal men (testosterone &lt; 12 nmol/L and symptoms) with poorly controlled diabetes, HbA1c &gt; 53 mmol/mol</p><p><b>Exclusion criteria: </b>NA</p><p><b>Total number of participants randomly assigned: </b>65</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: NA</li><li>Age (mean, range): 59 (42 to 77) overall</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: NA</li><li>Age (mean): 59 (42 to 77) overall</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A:</b> TU IM (Nebido®) every 12 weeks</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>6 months</p>,"<p><b>Outcomes</b></p><ol><li>Symptoms and QoL&nbsp;</li><li>Metabolic and anthropometric measurements&nbsp;</li></ol><p>How measured:</p><ol><li>AMS, SF-36, IIEF-5, Mini Mental State Examination, Barnsley Diabetes Hypogonadism Questionnaire, New England Research Institutes hypogonadism questionnaire</li><li>Fasting triglycerides, HbA1c, hand-grip strength</li></ol><p>Time points measured: at baseline and every 3 months</p><p>Time points reported: at baseline and 6 months</p><p><b>Safety outcomes: </b>NR</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,"<p>To assess the effect of IM testosterone on symptom severity, QoL, and metabolic parameters in men with hypogonadism and poorly controlled type 2 diabetes</p>",<p>Language of publication: English</p>
Reiter 1999,1999,PUB,22923565,,"<p><b>Study design: </b>prospective, double-blind, randomized, placebo-controlled study</p><p><b>Setting/country: </b>single center/Austria</p><p><b>Dates when study was conducted: </b>October 1996 to August 1997</p>","<p><b>Inclusion criteria:</b></p><ul><li>History of ED for more than 6 months</li><li>Serum levels of T, PRL, and PSA within the normal range, and a serum DHEAS level below 1.5 μmol/L</li><li>IPSS below 7 and a full erection after intracavernosal administration of 10 μg prostaglandin E1</li></ul><p><b>Exclusion criteria: </b>patients with well-known causes for ED, such as hypertension, diabetes mellitus, ischemic heart disease, hyperlipidemia, neurologic disorders, veno-occlusive dysfunction, and a history of radical prostatectomy</p><p><b>Total number of participants randomly assigned: </b>40</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (median (IQR)): 56.6 (43 to 68) years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean): 13.88 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean): 1.4 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (median (IQR)): 56.4 (41 to 69) years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean): 15.27 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean): 1.4 ng/mL</li></ul>",<p><b>Group A: </b>oral dose of 50 mg of DHEA</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>24 weeks</p>,"<ol><li>Erectile function</li><li>Sexual quality of life</li><li>Sexual desire</li><li>Orgasmic function</li></ol><p>How measured: </p><ol><li>IIEF-EF</li><li>Intercourse satisfaction domain and overall satisfaction domain of IIEF</li><li>Sexual desire domain of IIEF</li><li>Orgasmic function of IIEF</li></ol><p>Time points measured: baseline, 8, 16, 24 weeks</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> NA</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To evaluate the efficacy of DHEA replacement in the treatment of ED</p>,<p><b>Language of publication: </b>English</p>
Roth 2011,2011,PUB,22923567,,"<p><b>Study design: </b>prospective, randomized, double‐blind, placebo‐controlled trial</p><p><b>Setting/country:</b> NA</p><p><b>Dates when study was conducted:</b> NA</p>",<p><b>Inclusion criteria: </b>men 60 years old or greater with borderline low T with mild to moderate ED</p><p><b>Exclusion criteria:</b> NA</p><p><b>Total number of participants randomly assigned: </b>167</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 55</li><li>Age (mean ± SD): 64 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>SHIM (mean ± SD): 17.5</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 56</li><li>Age (mean ± SD): 65 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>SHIM (mean ± SD): 16.1</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group C</b></p><ul><li>Number of all participants randomly assigned: 56</li><li>Age (mean ± SD): 65 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>SHIM (mean ± SD): 15.9</li><li>PSA (mean ± SD): NA</li></ul>,"<p><b>Group A: </b>standard-dose testosterone gel, 50 mg/d</p><p><b>Group B: </b>low-dose testosterone gel, 25 mg/d</p><p><b>Group C: </b>placebo</p><p><b>Follow-up: </b>12 months</p>","<ul><li>Erectile dysfunction</li></ul><p>How measured: SHIM</p><p>Time points measured: baseline, 6, 12 months</p><p>Time points reported: at baseline</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> NA</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To evaluate the effect of testosterone supplementation on sexual function in men over 60</p>,<p><b>Language of publication: </b>English</p>
Schiavi 1997,1997,PUB,22923569,,"<p><b>Study design: </b>double-blind, placebo-controlled, cross-over study</p><p><b>Setting/country: </b>single center/USA</p><p><b>Dates when study was conducted: </b>May 1992 to December 1993</p>","<p><b>Inclusion criteria:</b></p><ul><li>Age: 45 to 74</li><li>Married or living with a sexual partner for at least 1 year</li><li>Possession of a high school diploma</li><li>English as the primary language</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Evidence of a medical disorder</li><li>Drug intake, especially medications with neurological, vascular, or endocrine action</li><li>Alcohol or other substances of abuse</li><li>Presence of major psychopathology</li><li>Obesity (more than 20% above ideal body weight according to the 1983 Metropolitan Life Insurance Tables)</li></ul><p><b>Total number of participants randomly assigned: </b>NA</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: NA</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 14.30 ± 1.67 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: NA</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): 16.69 ± 7.11 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>TU IM 200 mg followed by placebo</p><p><b>Group B: </b>placebo followed by TU IM 200 mg</p><p><b>Follow-up: </b>10 weeks (including a washout period of 4 weeks)</p>,"<p><b>Primary outcomes</b></p><ul><li>Sexual behavior</li></ul><p>How measured: brief sexual function questionnaire</p><p>Time points measured: baseline, 2, 4, 6 weeks</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ol><li>Mood</li><li>Psychological symptoms</li></ol><p>How measured:</p><ol><li>POMS</li><li>SCL-90-R</li></ol><p>Time points measured: baseline, 2, 4, 6 weeks</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: National Institute on Aging Grant AG-06895</p><p>Declarations of interest: NR</p>,"<p>To assess the effect of testosterone on the sexual behavior, mood, and psychological symptoms of a group of eugonadal men with ED</p>",<p><b>Language of publication: </b>English</p>
Seftel 2004,2004,PUB,22923571,,"<p><b>Study design: </b>randomized, multidose, multicenter, active, placebo-controlled study</p><p><b>Setting/country: </b>multicenter/USA</p><p><b>Dates when study was conducted:</b> NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Participants were between 20 and 80 years of age (mean age 58 years)</li><li>Morning T level ≤ 300 ng/dL (10.4 nmol/L) at screening</li><li>One or more symptoms of low T (i.e. fatigue, decreased muscle mass, reduced libido, reduced sexual functioning of a non-mechanical nature)</li><li>Generally good health</li></ul><p><b>Exclusion criteria:</b> NA</p><p><b>Total number of participants randomly assigned: </b>406</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 106</li><li>Age (mean ± SD): 56.8 ± 10.6 years</li><li>BMI (mean ± SD): 29.9 ± 3.3 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 8.05 ± 2.15 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 99</li><li>Age (mean ± SD): 58.1 ± 9.7 years</li><li>BMI (mean ± SD): 30.0 ± 3.7 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 8.11 ± 1.98 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group C</b></p><ul><li>Number of all participants randomly assigned: 102</li><li>Age (mean ± SD): 60.5 ± 9.7 years</li><li>BMI (mean ± SD): 29.9 ± 3.8 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 8.30 ± 2.39 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group D</b></p><ul><li>Number of all participants randomly assigned: 99</li><li>Age (mean ± SD): 56.8 ± 10.8 years</li><li>BMI (mean ± SD): 30.3 ± 3.8 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 7.93 ± 2.79 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: 100&nbsp;mg</b>/d T gel</p><p><b>Group B: </b>50 mg/d T gel</p><p><b>Group C: </b>100 mg T patch</p><p><b>Group D: </b>placebo</p><p><b>Follow-up: </b>3 months</p>,"<ul><li>Sexual function</li></ul><p>How measured: self-report daily diary</p><p>Time points measured: 30, 90 days</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: mean testosterone levels</p><p>Time points measured: baseline, 30, 90 days</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: Auxilium Pharmaceuticals, Inc, Norristown, Pennsylvania</p><p>Declarations of interest: NR</p>",<p>T supplementation in hypogonadal men with sexual dysfunction will restore certain elements of sexual function</p>,<p><b>Language of publication: </b>English</p>
Shabsigh 2004a,2004,PUB,22923574,,"<p><b>Study design: </b>randomized, placebo-controlled, double-blind, parallel-group, multicenter study</p><p><b>Setting/country: </b>multicenter/USA</p><p><b>Dates when study was conducted: </b>October 2001 to November 2002</p>",<p><b>Inclusion criteria:</b></p><ul><li>Men 18 to 80 years old</li><li>ED for 3 months or greater</li><li>Stable sexual relationship with a female partner for 6 months or greater</li><li>Morning serum TT level of 400 ng/dL or less at visits 1 and 2</li><li>Non-responders to sildenafil monotherapy (defined as a score of 2 or 3 on questions 3 and 4 of IIEF)</li></ul><p><b>Exclusion criteria:&nbsp;</b></p><p>Men with the following.</p><ul><li>History of prostate or breast cancer</li><li>Clinically significant or uncontrolled medical or psychiatric conditions (including diabetes mellitus)</li><li>Neurological disorders that cause ED</li><li>Generalized skin disease that may affect T-gel absorption</li><li>Hyperprolactinemia (serum prolactin greater than 25 ng/mL)</li><li>Drug or alcohol abuse</li></ul><p><b>Total number of participants randomly assigned: </b>75</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned:39</li><li>Age (mean ± SD): 56.8 ± 10.2 years</li><li>BMI (mean ± SD): 31.5 ± 5.2 mL</li><li>Testosterone (mean ± SD): NA</li><li>Overall IIEF (mean ± SD): 41.1 ± 8.4</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 36</li><li>Age (mean ± SD): 59.1 ± 9.4 years</li><li>BMI (mean ± SD): 31.3 ± 5.5 mL</li><li>Testosterone (mean ± SD): NA</li><li>Overall IIEF (mean ± SD): 41.4 ± 10.3</li><li>PSA (mean ± SD): NA</li></ul>,<p><b>Group A: </b>1% (5 g/d) testosterone gel + 100 mg sildenafil</p><p><b>Group B: </b>5 g placebo gel + 100 mg sildenafil</p><p><b>Follow-up: </b>12 weeks</p>,"<p><b>Primary outcomes</b></p><ul><li>Sexual function</li></ul><p>How measured: IIEF</p><p>Time points measured: baseline, 4, 8, 12 weeks</p><p>Time points reported: baseline, 4, 8, 12 weeks</p><p><b>Secondary outcomes</b></p><ul><li>Frequency of successful sexual activity</li><li>GAQ</li><li>QoL</li><li>Serum total and free T levels</li></ul><p>How measured: NA</p><p>Time points measured: baseline, 4, 8, 12 weeks</p><p>Time points reported: baseline, 4, 8, 12 weeks</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,"<p>Funding sources: Solvay Pharmaceuticals, Inc.</p><p>Declarations of interest: NR</p>",<p>To compare the efficacy of testosterone gel (T gel) versus placebo as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone</p>,<p><b>Language of publication: </b>English</p>
Snyder 2016,2016,PUB,22923579,NCT00799617,"<p><b>Study design: </b>double-blinded, placebo-controlled trial</p><p><b>Setting/country: </b>multicenter/USA</p><p><b>Dates when study was conducted: </b>June 2010 to June 2014</p>","<p><b>Inclusion criteria:</b></p><ul><li>Age: more than 65 years</li><li>Total testosterone values: initial T &lt; 275 ng/dL, a second &lt; 300 ng/dL, and an average &lt; 275 ng/dL</li><li>DISF-SDD: score &lt; 20</li><li>Heterosexual partner willing to have sexual intercourse at least twice a month</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Diagnosed prostate cancer or prostatic intraepithelial neoplasia</li><li>Risk of prostate cancer by the Prostate Cancer Risk Calculator: 35% of overall prostate cancer or 7% risk of high-grade prostate cancer</li><li>Severe lower urinary tract symptoms on the International Prostate Symptom Score questionnaire (score of &gt; 19)&nbsp;</li><li>Sleep apnea, diagnosed but untreated</li><li>Illnesses or medications that would interfere with interpretation of the results</li><li>Medications that affect serum testosterone concentration</li></ul><p><b>Total number of participants randomly assigned:</b> 790</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 395</li><li>Age (mean ± SD): 72.1 ± 5.7 years</li><li>BMI (mean ± SD): 31.0 ± 3.5 kg/m²</li><li>Testosterone (mean ± SD): 8.0 ± 2.2 nmol/L</li><li>IIEF-EF (mean ± SD): 8.1 ± 8.1</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 395</li><li>Age (mean ± SD): 72.3 ± 5.8 years</li><li>BMI (mean ± SD): 31.0 ± 3.6 kg/m²</li><li>Testosterone (mean ± SD): 8.2 ± 2.3 nmol/L</li><li>IIEF-EF (mean ± SD): 7.8 ± 8.3</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>testosterone gel 1% in a pump bottle 5 g daily</p><p><b>Group B: </b>placebo gel</p><p><b>Follow-up:</b> 12 months</p>,"<p><b>Primary outcomes</b></p><ul><li>Change in sexual activities</li></ul><p>How measured: question 4 of the PDQ</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ol><li>Measures of sexual desire</li><li>Erectile and orgasmic function</li></ol><p>How measured:</p><ol><li>DISF-SDD</li><li>IIEF, EFD, organism function domain of IIEF</li></ol><p>Time points measured:</p><ol><li>Baseline, 3, 6, 9, 12 months</li><li>NA</li></ol><p>Time points reported: NA</p><p><b>Safety outcomes</b>: NA</p><p><b>Subgroup:</b> none</p>",<p>NCT00799617</p>,"<p>Funding sources: National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Neurological Diseases and Stroke, and National Institute of Child Health and Human Development, AbbVie</p><p>Declarations of interest: grants and personal fees from the NIA, CTSI, the National Institute of Diabetes and Digestive and Kidney Diseases, AbbVie, Merck Sharpe &amp; Dohme, GlaxoSmithKline, Endo Health Solutions, Eli Lilly, Pfizer, Besins Health International, Clarus Therapeutics, University of Florida, National Institute of Nursing Research, Regeneron, Transition Therapeutics, Sanofi, Ardana, and Endo Pharma. Authors served as a consultant to AbbVie, Apricus, Besins, Clarus Therapeutics, Endo Pharma, Ferring, Lilly, Pfizer, and Repros Therapeutics, and Watson Laboratories.</p>","<p>To assess the responsiveness of specific sexual activities to T treatment, to relate hormone changes to changes in sexual function, and to determine predictive baseline characteristics and T threshold for sexual outcomes</p>",<p><b>Language of publication: </b>English</p>
Spitzer 2012,2012,PUB,22923586,NCT00512707,"<p><b>Study design: </b>randomized, double-blind, placebo-controlled trial</p><p><b>Setting/country: </b>NA/USA</p><p><b>Dates when study was conducted: </b>November 2006 to May 2010</p>","<p><b>Inclusion criteria:</b></p><ul><li>ED as defined by a score of 25 or less on the erectile function domain of IIEF</li><li>Age between 40 and 70 years</li><li>Serum T measured using LCMS/MS &lt; 11.5 nmol/L (330 ng/dL) and/or free T &lt; 173 pmol/L (50 pg/mL)</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Prostate cancer</li><li>Creatinine &gt; 180 μmol/L (2 mg/dL)</li><li>HbA1c &gt; 8.5%</li><li>PSA &gt; 4 ng/mL</li><li>BP &gt; 160/100 mmHg</li><li>MI or stroke within 6 months, or congestive heart failure</li><li>Use of androgens, antiandrogens, or nitrates</li><li>Medications that influence androgen levels, such as high-dose opiates, glucocorticoids, or antiepileptics</li></ul><p><b>Total number of participants randomly assigned: </b>140</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 70</li><li>Age (mean ± SD): 55.1 ± 8.3 years</li><li>BMI (mean ± SD): 31.5 ± 6.4 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 8.61 ± 2.15 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 70</li><li>Age (mean ± SD): 54.6 ± 8.5 years</li><li>BMI (mean ± SD): 32.7 ± 6.0 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 8.81 ± 2.36 nmol/L</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>topical 1% testosterone gel (10 g daily)</p><p><b>Group B: </b>placebo gel daily</p><p><b>Follow-up: </b>14 weeks</p>,"<p><b>Primary outcomes</b></p><ul><li>Well-being and mood</li></ul><p>How measured: PGWBI, DABS</p><p>Time points measured: baseline, 8, 14 weeks</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ul><li>Prostate-related events</li></ul><p>How measured: PSA, prostate exams</p><p>Time points measured: NA</p><p>Time points reported: baseline, 8, 14 weeks</p><p><b>Safety outcomes</b></p><p>How measured: adverse events; hematocrit</p><p>Time points measured: NA</p><p>Time points reported: baseline, 8, 14 weeks</p><p><b>Subgroup:</b> </p><ul><li>Age: &lt; 55.5, ≥ 55.5</li><li>Obesity: &lt; 30, ≥ 30</li><li>Response to sildenafil alone: change in EFD of IIEF &lt; 4, change in EFD of IIEF ≥ 4</li><li>Baseline serum total testosterone level: &lt; 8.68, ≥ 8.68</li></ul>",<p>NCT00512707</p>,"<p>Funding sources: National Institute of Child Health and Human Development, Boston University Clinical and Translational Science Institute, and Boston Claude D. Pepper Older Americans Independence Center</p><p>Declarations of interest: none</p>",<p>To determine whether the addition of testosterone to sildenafil therapy improves erectile response in men with erectile dysfunction and low testosterone levels</p>,<p><b>Language of publication: </b>English</p>
Yucel 2017,2017,PUB,22923591,,"<p><b>Study design: </b>prospective, randomized, placebo-controlled clinical trial</p><p><b>Setting/country: </b>multicenter/Turkey</p><p><b>Dates when study was conducted:</b> NA</p>","<p><b>Inclusion criteria:</b></p><ul><li>Aged between 24 and 76 years</li><li>With AMS scores over 27</li><li>Total serum testosterone level below 350 ng/dL (12.1 nmol/L) who presented to the urology clinic with complaints of LUTS and ED</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Patients who had chronic diseases (diabetes, hyperlipidemia, hypertension, or cardiovascular disease), malignancy, psychiatric disorders</li><li>Abnormal digital rectal examination</li><li>Elevated serum PSA levels &gt; 4 ng/mL</li></ul><p><b>Total number of participants randomly assigned: </b>62</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 31</li><li>Age (mean ± SD): 57.6 ± 15.8 years</li><li>BMI (mean ± SD): 29.2 ± 4.8 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 9.6 ± 2.0 nmol/L</li><li>EF (mean ± SD): 15 ± 5</li><li>PSA (mean ± SD): 0.021 ± 0.007 ng/mL</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 31</li><li>Age (mean ± SD): 61.7 ± 11.7 years</li><li>BMI (mean ± SD): 29.1 ± 6.4 kg/m<sup>2</sup></li><li>Testosterone (mean ± SD): 9.3 ± 1.5 nmol/L</li><li>EF (mean ± SD): 12.7 ± 4.6</li><li>PSA (mean ± SD): 0.019 ± 0.008 ng/mL</li></ul>","<p><b>Group A: </b>transdermal testosterone, 50 mg daily</p><p><b>Group B: </b>placebo</p><p><b>Follow-up: </b>3 months</p>","<p><b>Primary outcomes</b></p><ol><li>LUTS</li><li>Erectile function</li></ol><p>How measured: </p><ol><li>Uroflow rate test (uroflowmetry), IPSS</li><li>IIEF-5</li></ol><p>Time points measured: baseline, 1, 3 months</p><p>Time points reported: baseline, 1, 3 months</p><p><b>Secondary outcomes</b></p><ul><li>Sexual quality of life</li></ul><p>How measured: AMS</p><p>Time points measured: baseline, 1, 3 months</p><p>Time points reported: baseline, 1, 3 months</p><p><b>Safety outcomes</b></p><p>How measured: serum total testosterone; PSA, Qmax</p><p>Time points measured: 0, 1 month, 3 months</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To evaluate the effects of transdermal testosterone administration on LUTS and ED</p>,<p><b>Language of publication: </b>English</p>
Zhang 2012,2012,PUB,22923593,,<p><b>Study design: </b>randomized study</p><p><b>Setting/country:</b> NA</p><p><b>Dates when study was conducted:</b> NA/China</p>,<p><b>Inclusion criteria: </b>type 2 diabetic patients with ED</p><p><b>Exclusion criteria:</b> NA</p><p><b>Total number of participants randomly assigned: </b>40</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>IIEF-5 (mean ± SD): 10.8 ± 1.9</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 20</li><li>Age (mean ± SD): NA</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>IIEF-5 (mean ± SD): 11.3 ± 2.1</li><li>PSA (mean ± SD): NA</li></ul>,"<p><b>Group A: </b>Andriol, 40 mg twice daily</p><p><b>Group B: </b>only sildenafil 50 mg before sexual activity</p><p><b>Follow-up: </b>12 weeks</p>","<p><b>Primary outcomes</b></p><ul><li>Erectile function</li></ul><p>How measured: IIEF-5 </p><p>Time points measured: baseline, 12 weeks</p><p>Time points reported: baseline, 12 weeks</p><p><b>Secondary outcomes</b></p><ul><li>Intercourse satisfaction</li></ul><p>How measured: NA</p><p>Time points measured: baseline, 12 weeks</p><p>Time points reported: NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: baseline, 12 weeks</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To compare the efficacy and safety of sildenafil plus undecanoate (Andriol) with those of sildenafil alone in the treatment of T2DM with ED</p>,<p><b>Language of publication: </b>English</p>
Zhong 2013,2013,PUB,22923595,,<p><b>Study design: </b>randomized study</p><p><b>Setting/country: </b>multicenter/China</p><p><b>Dates when study was conducted: </b>January 2009 to February 2011</p>,"<p><b>Inclusion criteria:&nbsp;</b></p><p>Men with the following.</p><ul><li>Typical diabetes symptoms associated with blood glucose &gt; 11.1 mmol/L or FPG &gt; 7.0 mmol/L</li><li>IIEF-5 score &lt; 21</li><li>Disease duration: more than 3 months</li><li>Fixed sexual partner and regular sexual life, normal genital development</li><li>Low TT levels</li></ul><p><b>Exclusion criteria:</b></p><ul><li>Patients with prostate and suspicion of prostate cancer</li><li>Patients with benign prostatic hyperplasia and severe lower urinary tract obstruction</li><li>Patients with severe obstructive sleep apnea syndrome</li><li>People with a history of mental illness, such as alcohol, psychoactive drugs etc., who have serious illnesses or physical conditions that are not suitable for sexual life</li><li>Patients who are currently taking nitrates, antiandrogens, or tumor chemotherapy drugs in any dosage form</li></ul><p><b>Total number of participants randomly assigned: </b>100</p><p><b>Group A</b></p><ul><li>Number of all participants randomly assigned: 50</li><li>Age (mean ± SD): 63.0 ± 2.5 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul><p><b>Group B</b></p><ul><li>Number of all participants randomly assigned: 50</li><li>Age (mean ± SD): 62.0 ± 3.0 years</li><li>BMI (mean ± SD): NA</li><li>Testosterone (mean ± SD): NA</li><li>EF (mean ± SD): NA</li><li>PSA (mean ± SD): NA</li></ul>",<p><b>Group A: </b>testosterone undecanoate (80 mg/twice a day) + sildenafil</p><p><b>Group B: </b>only sildenafil</p><p><b>Follow-up: </b>12 weeks</p>,"<p><b>Primary outcomes</b></p><ul><li>Erectile dysfunction</li></ul><p>How measured: IIEF-5</p><p>Time points measured: baseline, 12 weeks</p><p>Time points reported: NA</p><p><b>Secondary outcomes</b></p><ul><li>Weekly sexual intercourse frequency and sexual life satisfaction</li></ul><p>How measured:NA</p><p>Time points measured: baseline, 12 weeks</p><p>Time points reported:NA</p><p><b>Safety outcomes</b></p><p>How measured: NA</p><p>Time points measured: NA</p><p>Time points reported: NA</p><p><b>Subgroup:</b> none</p>",<p>NA</p>,<p>Funding sources: NR</p><p>Declarations of interest: NR</p>,<p>To study the effects and safety of sildenafil combined with testosterone undecanoate for the treatment of ED with diabetes</p>,<p><b>Language of publication: </b>English</p>
